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AIMS: 
 
To examine the relationship between prospective memory, cognitive function 
and Diffusion tensor imaging (DTI)/ White matter integrity of human 
immunodeficiency virus (HIV) positive individuals in the Western Cape.  We 
hypothesize that:   
1.  Individuals infected with HIV will exhibit significantly poorer microstructural 
integrity of the white matter than HIV negative individuals, as determined by in 
vivo diffusion tensor imaging.  We expect that values of fractional anisotropy 
(FA) - a measure of directional water diffusion- in the frontal white matter will 
be significantly lower among HIV patients compared to controls  
2.  Lower FA measured in the frontal white matter will correlate significantly 
with impaired performance on tests of prospective memory  
 
INTRODUCTION 
 
Neuropsychological impairment in HIV 
Neuropsychological impairment is evident in 30 to 50% of persons with HIV-1 
disease, with the characteristic pattern of deficits thought to reflect a 
preferential disruption of prefronto-striatal circuits (Reger, 2002). Deficits in 
motor coordination, information processing speed, working memory, and 
executive functions are commonly associated with HIV-1 (e.g., Heaton et al., 
1995). 
 
Deficient episodic (i.e., retrospective) learning and retrieval are common in 
individuals with HIV-1 infection (Murji et al., 2003). Group studies of HIV-1 
disease reveal evidence of limited free recall, diminished use of organizational 
strategies (e.g., semantic clustering), interference effects, inconsistent recall 
across learning trials, and high rates of repetition errors (Murji et al., 2003). By 
way of comparison, retention (i.e., consolidation) and recognition 
discrimination are less commonly affected in persons with HIV-1 disease (e.g., 
Delis et al., 1995). Taken together, the memory profile of HIV-1-infection is 
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most consistent with dysfunction in the strategic (i.e., executive) aspects of 
encoding and retrieval as seen in prototypical “subcortical” disorders, such as 
Parkinson’s and Huntington’s diseases (Murji et al., 2003). 
 
The neuropsychological features of HIV associated dementia (HAD) are 
indicative of the neuro-pathological changes. Therefore, HIV-associated 
degeneration of sub-cortical striatal and fronto-striatal structures leads to 
motor/psychomotor problems, memory dysfunction and frontal/executive 
dysfunction (Grant et al 2005). More specifically, motor problems are seen on 
the timed gait and grooved pegboard tests; memory is impaired mainly in its 
recall domain, and less in recognition; while frontal/executive problems are 
observed during tests of verbal fluency, set-shifting (trail making) and slowed 
information processing.  
 
It is unclear how neuropsychological impairment relates to neuro-
degeneration. A likely summary is that HIV continues to replicate within the 
central nervous system (CNS) during the clinically asymptomatic phase, with 
periods of enhanced replication and consequent CD4 cell loss. These effects 
may be attenuated by highly active antiretroviral therapy (HAART). Lastly, 
there is a predictably strong association between neuropsychological 
impairment and post-mortem evidence for HIV-encephalitis (which is defined 
by myelin pallor, multi-nucleated giant cells and microglial nodules) (Cherner 
et al 2002). 
 
One cognitive construct with obvious relevance to medication adherence is 
prospective memory (ProM). ProM, or “remembering to remember”, is an 
aspect of declarative memory that refers to the execution of a future intention 
(e.g., remembering to pay one’s rent at the beginning of the month). 
Recent research shows that individuals infected with HIV report experiencing 
more frequent prospective memory (ProM) failures as compared to 
demographically similar seronegative persons, especially on self-cued daily 
tasks (Carey, et al., 2007).  Consistent with the largely frontal systems 
neuropathophysiology of HIV the profile of HIV-associated ProM impairment is 
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characterized by deficient self-initiated cue detection and retrieval (Carey et 
al., 2006).  
ProM generally involves a series of cognitive processes that includes: (1) the 
formation of an intention that is paired with a specific retrieval cue (i.e., a 
specific 
time or event); (2) maintenance of the intention-cue pairing over a delay 
interval while concurrently engaged in a foreground task, during which time 
both active (e.g., strategic) and automatic (i.e., spontaneous) monitoring may 
occur (McDaniel 2007); (3) detection and recognition of the cue; (4) search 
and retrieval from retrospective memory (RetM) for the content of the 
intention; and (5) successful execution of the intention. At a neural systems 
level, ProM is most heavily reliant upon prefrontal systems (e.g., Brodmann’s 
area 10; Simons, 2006), but is also dependent upon the RetM contribution of 
medial temporal (e.g., hippocampal) networks (e.g., Martin, McDaniel, et al., 
2007). 
An important distinction is often made between event-based (EB) and time-
based (TB) ProM tasks (Einstein & McDaniel, 1990). The difference between 
these two tasks concerns the type of cues that initiate retrieval of the intention. 
For example, an external stimulus (sometimes embedded in an ongoing 
activity) provides the cue for action in an EB task (e.g., a mailbox cues the 
mailing of a letter), whereas in TB tasks, the intended action is performed after 
a specified time interval (e.g., taking a medication every four hours). It has 
been hypothesized that TB tasks require slightly different cognitive processes 
than EB tasks (i.e., a greater emphasis on self-initiated monitoring and 
retrieval), and empirical evidence suggests that the former are generally more 
sensitive in older adults (Henry, MacLeod, Phillips, & Crawford, 2004) and 
traumatic brain injury samples (e.g., Cockburn, 1996). 
 
 From a more practical perspective, ProM is hypothesized to play a unique 
and influential role in numerous aspects of daily life, including household 
chores (e.g., cooking; Fortin, 2002) and employment (e.g., Sellen,  2007). 
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Why prospective memory is important? 
ProM is critical in order to properly adhere to a medication regimen; that is, 
one must first form the intention to take the medication at some point in the 
future (e.g., take two pills of medication X after dinner), maintain the intention-
cue pairing throughout the day despite the distraction of normal daily 
activities, detect and recognize the cue when it occurs (e.g., clearing the 
dinner table), recall the specific medication and directions, and finally, take the 
medication as instructed.  (Woods 2008)  
Prior studies in HIV (e.g., Hinkin et al., 2002), standard clinical measures of 
executive functions (i.e., planning and divided attention), attention, episodic 
retrospective memory, and verbal fluency were also predictive of medication 
management. HIV-associated ProM impairment emerged as a significant 
predictor of medication management, even after considering the contributions 
of these established cognitive domains.  
 
Strict adherence to prescribed medication regimens (i.e., HAART) is essential 
to the long-term clinical management of HIV disease. Infected individuals who 
are highly adherent (i.e., taking over 90% of their prescribed doses) evidence 
considerably better disease outcomes, including lower rates of virologic 
failures (Perno et al., 2002), treatment resistant viral strains (Harrigan et al., 
2005), and mortality (Lima et al., 2007).  Mild-to-moderate deficits in 
numerous areas of neuropsychological functioning (e.g., memory, executive 
functions, information processing speed) remain prevalent in the era of 
HAART, despite the effectiveness of such treatments on immune health.  
 
 
As many as one half of individuals with HIV associated neurocognitive 
impairment experience problems with independently managing their 
instrumental activities of daily living (IADLS) (Heaton et al., 2004).  These 
findings converge with a recent study showing that ProM demonstrates 
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incremental ecological validity as a predictor of general IADL dependence in 
HIV (Woods et al, 2008). 
Neuropsychological impairment contributes to decrements in medication 
management, automobile driving and vocational functioning even after one 
considers the effects of HIV disease severity and psychiatric distress (van 
Gorp et al., 1999).  Woods et al.  (2008) showed that Prospective memory 
plays an important and unique role in successful daily functioning among 
individuals infected with HIV. 
 
What is known about HIV and the brain? 
At present the neurobiological substrates of HIV cognitive impairment are not 
well described.  This is particularly the case for the genetic form of HIV known 
as clade C, since nearly all studies of cognitive function in HIV have been 
conducted in North America where the dominant genetic strain of the virus is 
clade B.  Early studies suggested that individuals infected with clade C may 
be less likely to develop cognitive impairments due to a biological defect in the 
tat protein present in clade C (Ranga et al., 2004).  Tat protein is thought to be 
an important mediator of the neuro-toxic effects of HIV.  
 
In recently published data from India, it was shown that individuals infected 
with clade C exhibit significant cognitive impairment, suggesting that the brain 
is, in fact, vulnerable among individuals with clade C HIV (Yepthomi et al., 
2006).   These findings are notable because clade C is the most common 
form of HIV in the world, as well as the dominant strain in South Africa. 
 
The importance of this distinction is that the two strains of the virus differ in 
terms of specific protein binding sites and binding characteristics, replicative 
capacity (Centlivre et al., 2005), and possibly in the development of treatment 
resistance (Grossman et al., 2001; Kantor et al., 2002), all of which suggests 
a potentially different outcome associated with the clade C viral strain.  
 
HIV-associated neuropathologies predominantly affect the 
frontostriatothalamocortical circuits which are known to support normal ProM 
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functioning.    Two of the principal components of prospective memory (i.e., 
remembering to carry out delayed intentions) are recognizing the appropriate 
context to act (“cue identification”) and remembering the action to be 
performed (“intention retrieval”). In a functional MRI (fMRI) study, it was found 
that a consistent pattern of hemodynamic changes occurred in both 
prospective memory conditions/components in anterior prefrontal cortex 
(Brodmann area 10- BA 10), with lateral BA 10 activation accompanied by 
medial BA 10 deactivation. These effects were more pronounced when 
demands on intention retrieval were high. This is consistent with the 
hypothesis that anterior prefrontal cortex (area 10) supports the biasing of 
attention between external events (e.g., identifying the cue amid distracting 
stimuli) and internal thought processes (i.e., maintaining the intention and 
remembering the intended actions). The results suggest that cue identification 
and intention retrieval share some common neural basis in anterior prefrontal 
cortex.  (Simons et al 2006).  Recent studies implicate the contribution of 
hippocampal neuropathology to HIV-associated episodic memory deficits.  
(Moore et al 2006) and demonstrate that ProM is impaired in conditions with 
prominent involvement of the medial temporal lobe, such as Alzheimer’s 
disease (Duchek et al 2006).  Prior studies of ProM among individuals with 
HIV (Carey et al 2006) postulated that HIV associated neural injury disrupts 
the executive aspects of encoding and retrieval of future intentions. 
 
White matter abnormalities have been described in HIV, but structural MRI 
may lack the sensitivity to detect pathological changes (i.e., normal appearing 
white matter).  A more sensitive approach is diffusion tensor imaging (DTI).  
DTI measures the random thermal motion of water in brain tissue (Tuch et al 
2003).  Water diffusion along directional pathways (e.g., white matter) occurs 
preferentially along the axis of the pathway (anisotropic diffusion) compared to 
equally distributed movement (isotropic diffusion) in nondirectional regions 
(e.g., grey matter).  Alterations in myelin (e.g., Multiple Sclerosis) or changes 
to the microstructure of axonal projections reduce fractional anisotropy 
(Beaulieu 2002) and therefore DTI metrics are useful biomarkers of white 
matter integrity.  DTI in HIV has not been extensively researched to date, and 
the correlates between DTI and neuropsychiatry/neuropsychological 
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impairments is not known.  Patients with HIV had abnormalities despite 
normal-appearing white matter on MR images and nonfocal neurologic 
examinations. Patients with the highest diffusion constant elevations and 
largest anisotropy decreases had the most advanced HIV disease. (Filippi 
2001) 
 
A Cross-University Brain-Behaviour Initiative has recently been established 
between the Universities in the Cape, has taken delivery of a 3T Siemens 
MRI, which is one of the few such machines in the developing world, and is 
focused on attempting to develop capacity in MRI research that is relevant to 
local problems such as HIV. 
 
Conclusion 
Cognitive impairment in HIV is a common and debilitating condition. It impairs 
both the quality of life as well the adherence of affected individuals.  
Identifying salient risk factors for nonadherence and dependence in IALS is 
therefore of considerable public health importance, both in terms of facilitating 
early detection and informing targeted cognitive and behavioral interventions 
to maximize adherence. 
 
 
OBJECTIVES: 
1. To establish the prevalence of deficits in Prospective memory in a clinic 
population of HIV positive individuals attending ARV sites in the Western 
Cape  
i. to perform a detailed assessment of the presence of 
neurocognitive disorders including assessment of prospective 
memory in patients using the neuropsychological test battery, an 
assessment of functional status using the HNRC Activities of 
Daily Living Scale and the Patients’ Assessment of Own 
Functioning scale,. 
 
2. To establish the influence of selected other factors on ProM deficits.  
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i. to collect data from each patient with regard to age, gender, 
obstetric history, current adversity/life events, level of education 
(including pre-schooling), substance use, risk behaviour, 
medical history ,childhood psychiatric history and socioeconomic 
status 
ii. to obtain data on CD4 count, viral load, concurrent medical 
treatment, presence of neurological symptoms and signs  
 
 
3. To determine neuro-radiological correlates of neurocognitive disorders in 
particular ProM 
i. Obtain brain imaging data on subjects in order to delineate 
abnormalities of white matter, and correlates of change in 
cognitive function  
 
 
 
METHODS: 
Patients will be recruited from an existing study investigating 
neurocognitive deficits in patients infected with HIV.  The principal 
investigator on this project is Dr John Joska  
1. Subjects and sampling 
a. Patients will be recruited from Infectious Diseases clinics Khayelitsha Site 
C, Woodstock and Mitchells Plain Community Health Centres. Provincial 
approval has also been obtained from the Groote Schuur Hospital and GF 
Jooste Hospital ID clinics.  
b. It is intended to obtain a moderately representative sample of young adults 
attending public sector services in the Western Cape over the study 
period. Once the subject has been drawn by the study coordinator, he or 
she will be invited to participate in the study; should they decline, another 
subject will be drawn from the list. Eligible subjects are those who have 
attended the ARV clinic at least once, and are being counseled for 
commencement of ARV’s, and who meet inclusion criteria (as ascertained 
by a brief chart review and brief screening interview).   
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c. Subjects need to be able to provide full informed consent to participate in 
the study; they will sign full informed consent once it is confirmed that they 
are eligible and have agreed to participate. An arrangement for the study 
visits will then be made by the study coordinator. 
d. It is intended to include 45 patients in the study.  
 
2. Controls 
a. This study will use 10 cases as controls-Subjects tested as being HIV 
negative who attended the same ARV clinic as the subjects 
 
3. Inclusion criteria 
a. Young adults between the ages of 18 and 35 years will be included. In 
an older study population, age-consequent disease, such as 
neurodegenerative or cerebrovascular disease may have developed.  
b. Positive diagnosis of HIV infection made within the last six months 
(includes initial and confirmatory tests). 
c. Have not previously used anti-retroviral medications (“HAART naïve”) 
AND who being enrolled into anti-retroviral treatment. 
d. Patients who attend an out-patient clinic. 
e. Patients able to read and write to a grade 7 (std 5 level) 
 
4. Exclusion criteria 
a. Schizophrenia or bipolar disorder. 
b. Presence of uncontrolled medical condition, such as poorly controlled 
diabetes mellitus, epilepsy, active tuberculosis requiring admission or 
non-standard treatment (e.g. regimen 2).  
c. Presence of an identified central nervous system neurological 
condition, such as lymphoma, or untreated neuro-syphilis or 
cryptococcal infection. Patients who have had such conditions and who 
are deemed to have been fully treated are eligible for inclusion. 
d. Patients who have abused alcohol or other psycho-active substances 
within the preceding six months.   
e. History of a head injury with a duration of loss of consciousness of >30 
minutes, AND/OR requiring overnight admission to hospital. 
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f. Contra-indications to MRI- such as pregnancy, metal or claustrophobia. 
g. Patients who refuse to sign informed consent. 
5. Study design 
This is a two-group cross-sectional study of ProM and neuroimaging 
associated with clade C HIV.  Laboratory indices of HIV disease burden, 
neuroimaging and cognitive function will be collected from 45 seropositive 
individuals infected with clade C HIV and 10 healthy seronegative controls 
matched for age, education, and sex. Neurocognitive function will be 
measured with tests sensitive to cognitive impairment 
 
6. Instruments and measures 
The following measures have been selected. They include a range of both 
categorical (for example- the Miniature International Neuropsychiatric 
Interview Plus version (MINI+)) and continuous (International HIV\AIDS 
Dementia Rating Scale (IHDRS)) measures. The selected instruments meet 
criteria of validity, reliability and feasibility. See appendix 1 for summary of 
scales and instruments. Note: Neuropsychological test battery- This battery is 
based on a battery used in a previous local study and on a battery used by an 
international research group in HIV neuropsychology, together with input from 
local neuropsychologists. It includes tests of intelligence, attention, executive 
functions, and speed of processing and psychomotor function. These are 
areas mostly affected by HIV. A summary sheet is attached for information 
(appendix 2).  
 
Prospective memory assessment 
ProM will be measured using a subjective self report measure as well as 
objective measures.  The objective measure will consist of both a time and an 
event based task.  The event based task will be a measured using a measure 
previously used by Huppert et al., 2000 (High Prevalence of Prospective 
Memory Impairment in the Elderly and in Early-stage Dementia:  Findings 
from a Population-based Study, APPLIED COGNITIVE PSYCHOLOGY, 14: 
S63±S81).  The time based task will be one of the items from the MIST scale.   
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Objective event based prospective  
Prospective memory instructions were `Later on, I am going to give you a 
name and address to write on the envelope. When you have finished doing 
this, I would like you to do the following: turn it over, seal it and write your 
initials on the back. Could you remember to do this then without me reminding 
you'.  This was followed by a delay interval of around 10 minutes which was 
filled with other cognitive tasks. Then the envelope was shown and the 
interviewer said `Please write the following name and address on this 
envelope. The interviewer dictated the name and address slowly once, 
pausing at the end of the name, the house number, the street and the city, to 
keep pace with the respondent's writing speed, then said `Please go on 
remembering this name and address and I will ask you about it later'.  The 
interviewer then observed whether the respondent carried out the prospective 
memory task. If the respondent did not do so within about 5±10 seconds (the 
longer times were for slower respondents), the interviewer said `Were you 
going to do something else with the envelope' If only one correct action was 
carried out (i.e. just the envelope sealed or just initial written on the back), the 
interviewer said `Was there something else you were going to do' If the 
respondent wrote their name rather than their initials on the back of the 
envelope, this was scored as a correct response. 
 
Time based prospective memory 
Taken from the Memory for Intentions Screening Test (MIST; Raskin, 2004), 
which is a standardized laboratory measure of ProM with published evidence 
of its reliability  and construct validity (Carey et al., 2006).  
'In 2 minutes ask me when this session ends today  
 
 
Self-reported ProM is assessed using the ProM Scale from the Prospective 
and Retrospective Memory Questionnaire (PRMQ; Smith, Della Sala, Logie, & 
Maylor, 2000), which consists of eight ProM-specific items that are rated on a 
five-point Likert-type scale that ranges from 1 (“never”) to 5 (“very often”). The 
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PRMQ ProM complaints are separated into four self-cued (e.g., “How often do 
you forget appointments if you are not prompted by someone else or by a 
reminder, such as a diary or a calendar?”) and four environmentally cued 
(e.g., “How often do you forget to buy something you planned to buy, like a 
birthday card, even when you see the shop?”) Total scores on the PRMQ 
ProM Scale can range from 8 to 40.  These instruments will be forwards and 
back-translated into Afrikaans and isiXhosa, in order to be completed in the 
patient’s home language. 
In addition to these instruments, a detailed collection of socio-demographic 
data and personal history will be taken.  
 
Determination of dementia 
Each HIV individual will have his or her demographics, medical history, 
neurologic symptoms, functional status, neuropsychological test scores, and 
neurologic examination assessed by the primary examiners. Using all this 
information, a Memorial Sloan-Kettering (MSK) severity score of 0, 0.5, or 1.0 
will be assigned to each HIV individual. 
An MSK severity score of 0 represents no cognitive impairment, 0.5 
represents mild cognitive impairment not sufficient to meet criteria for 
dementia (subclinical), and a score of 1.0 represents dementia. An HIV 
positive subject is determined to be demented and given an MSK severity 
score of 1.0 if he or she has (scores less than 10 on the IHDS, and confirmed 
on neuropsychological testing, wherein two or more neuropsychological tests 
on which he or she scores 2 SD below the locally determined mean for their 
normative age and education group, and has symptomatic and/or functional 
complaints consistent with dementia or physical findings on neurologic exam 
consistent with HIV dementia such as extrapyramidal signs.. An HIV positive 
subject who scores 10-11 on the IHDS with abnormalities on only one or two 
neuropsychological tests in which they score from 1.0 to 2 SD below the 
locally determined mean for their normative age and education group, or an 
HIV positive subject with greater neuropsychological impairment but with no 
symptomatic or functional complaints and a normal neurologic examination 
will be given an MSK severity score of 0.5 (Wong et al 2007) 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 
Brain Imaging Protocol: Cognitive decline may present early in the course of 
HIV disease and be asymptomatic for some time. It is accompanied by 
changes in brain structure, function, blood-brain barrier integrity, and brain 
metabolites. In fact some of these changes are evident before clinical 
symptoms and cognitive deficits manifest themselves and are differ 
prospectively from HIV-negative controls.   Structural MRI will be performed to 
exclude intracerebral pathology. 
 
Imaging sequence is listed below. The total proposed imaging protocol 
duration is approximately 60 minutes.  
 
 3D T1 – MPRAGE – High resolution 3D-T1 image to be used as a 
basis for examining morphometric change in grey and white matter 
regional volumes prospectively. Imaging parameters include; 3D 
sagittal plane acquisition, TR 2300ms, TE 3.93ms, FOV 220mm and 
voxel size of 1mmx0.9x1mm. Sequence duration 6.53 min. This 
sequence will be repeated after gadolinium contrast enhancement 
adding another 6.53mins to the protocol.  
 3D T2 and FLARE sequences are most suited to examination of white 
matter signal changes from a variety of causes. TR 3500, TE 354, with 
an FOV of 256mm and slice thickness of 1mm and duration 9.25min. 
The heavily T2-weighted FLARE with TR 9000ms, TE 96ms, FOV 
220mm and slice thickness of 5mm. Sequence duration 2.26min.   
 A multi-direction diffusion weighted imaging (MDDW) sequence will be 
acquired to more specifically quantify the specific apparent diffusion co-
efficient (ADC) and fractional anisotropy (FA) of white matter in frontal, 
sub-cortical and callosal white matter fibres. This acquisition will also 
enable us to compute diffusion tensor from which directionality and 
density of white matter tracts can be defined in each group.  
Correlations with ProM deficits will be calculated. TR 5000ms, TE 
88ms, B= 0, 1000 and 30 diffusion directions for a sequence of 
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2.40mins in duration. Average of four repeats of this sequence will be 
used in analysis.  
7. Study procedure 
a. Clinical staff at the Khayelitsha site C, Woodstock and Mitchells Plain 
primary care ARV clinics will be informed about the study. Other sites 
may be added, with permission from the Provincial Health Department. 
b. Patients attending these services will be screened by attending clinical 
staff for inclusion and exclusion criteria. The investigator will be notified 
of a potential subject. 
c. Potential subjects will then be properly screened, and if suitable, will 
sign informed consent to enter the study. Subjects between the ages of 
18 and 21 will require the consent of a parent or legal guardian. 
d. At screening, patients will be asked about: 
- their medical (including head injuries) and HIV treatment history 
- their alcohol and substance abuse history (the AUDIT and the SAMISS 
will be used to aid in this enquiry. Significant overlap in these 
instruments) 
- their psychiatric history 
Following completion of informed consent- at the same clinic contact- 
subjects will complete the following self-report questionnaires: 
- Beck Depression Inventory 
- Life events questionnaire of Bruga 
- Childhood Trauma Questionnaire 
e. Subjects will then be referred to the Groote Schuur Hospital psychiatry 
out-patients department or the GF Jooste Hospital out-patients 
department (whichever is closest). The assessment will include of: 
MINI, MADRS, HDS, HADS, CTQ, LEQ, and MSSS. A second visit (#2) 
will be scheduled within 2 weeks to complete: neurocognitive profile 
and prospective memory assessment, service utilization, CAN, SDS 
and risk behaviour questionnaire. Data regarding medical and 
neurological problems will be retrieved from the patient notes. A 
neuromedical assessment will be performed according to a 
standardized brief scale. Patients will receive R30 per visit to 
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compensate for transport costs, plus an additional R26 rand to pay for 
out-patient fees.  
f. Brain imaging will be performed at the Cape Universities Brain Imaging 
Centre located at the Tygerberg Campus of Stellenbosch University. 
The imaging session will take approximately 1 hour to complete.  
g. All subjects will follow up with routine clinic services. Any who are 
diagnosed with psychiatric conditions will be treated by the study team, 
in the first instance, or by local mental health services, if the patient is 
unable to attend the study site for this care. 
h. Data on viral load\CD4 count and use of ARV’s will be obtained from 
the files at the hospital treating the subject.  
 
8. Data management and analysis 
Data will be captured directly into a study generated Case Report Form 
(CRF). This will include forms to capture demographic, clinical and serological 
data, as well as instruments. These data will then be entered into a Microsoft 
Excel Spreadsheet and cleaned. Once the data is clean, it will be analysed 
using SPSS statistical software package. Prevalence’s of disorders, symptom 
severity and impairment will be described using frequencies and percentages. 
Univariate analysis will be used to compare the frequencies of cognitive 
disorders in HIV positive subjects and controls, as well the frequencies of 
other neuropsychiatric disorders and possible contributory factors. A number 
of regression models will be fitted, whereby the presence of HIV-associated 
ProM disorder will be entered as the dependent variable, and a number of 
socio-demographic, clinical, and biochemical factors will be included as 
independent variables- these will include age, gender, level of education, 
history of head trauma, alcohol abuse, presence of neurological impairment, 
CD4 count and history of intra-cranial pathology in preceding 12 months. A 
biostatistician will be consulted for this.  
 
Regarding sample size and power analysis, it is assumed that significance 
tests will be performed at the 0.05 levels, and power to 80%.   The primary 
outcome is the prevalence of ProM disorder in the HIV positive population 
compared to controls.   
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Pomara in 2001 DTI was performed in six HIV-1 patients and nine controls. 
The two groups were similar in age. Abnormal fractional anisotropy was found 
in the white matter of the frontal lobes and internal capsules of the HIV-1 
patients (Pomara 2001).   
 
 
Time frame 
Study commencement: June 2009 
(Recruitment rate 4 per week= 64 subjects in 4 months subjects in one year) 
Field work complete: October 2009 
 
Data analysis: October 09-Nov09 
Study write-up: December 09-Jan 2010 
 
 
9. Ethical considerations 
This study will adhere to the principles laid down in the Helsinki Declaration 
(2002). Accordingly, this research is intended to “improve prophylactic, 
diagnostic and therapeutic procedures and the understanding of the etiology 
and pathogenesis of disease”, as it pertains to cognitive disorders in 
HIV/AIDS. The study has been approved by the Research Ethics Committee 
of the Faculty of Health Sciences of the University of Cape Town.  REC REF:  
263/2007 
 
a. Potential benefits and harms- patients included in this study will receive a 
detailed assessment of psychiatric, cognitive and other biopsychosocial 
parameters. Individuals with identified conditions will be referred to 
appropriate mental health services for care and treatment. Some patients may 
become distressed about re-discussing issues or may feel these were 
inadequately dealt with. These problems will be dealt with in a sensitive and 
professional manner within the study team. Other potential benefits include a 
greater awareness of mental health among community teams where the study 
will be conducted, and the reporting of results to both local role players and in 
the scientific community.  
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 
b. Equity and justice- The access to specialised mental health services, and 
particularly tertiary services, is limited within the public sector. It is hoped that 
this study will afford eligible patients the opportunity to undergo a 
comprehensive evaluation, while raising the profile of the problems that these 
patients have for all sufferers. In this way, it may be possible to offer a more 
comprehensive service once the need has been demonstrated.  
 
c. Informed consent- All patients will be provided with a patient information 
sheet in their first language which describes the scope and aims of this study 
(Xhosa and Afrikaans versions will be supplied to REC later, but prior to the 
study commencing). Patients who decide not to partake in this study will be 
reassured that their decision will not bias them or be held against them at any 
time in the future. Clinicians at other points of service will not be made of 
aware of patients not wanting to sign consent, or who do not meet inclusion 
criteria. Patients who have been fully informed about the study will then be 
invited to sign consent, which will be valid for the duration of the current 
protocol. Any amendments to this protocol, insofar as they affect patient care 
will be re-negotiated with them, and a new consent form signed. Patients will 
sign two copies of the consent form and will keep one copy for themselves. 
Patients who, in the opinion of the investigator, are deemed to be too unwell 
to sign informed consent, will be asked to sign, together with a member of 
his\her immediate family or next of kin. 
 
d. Confidentiality- Patients numbers will be used in order to manage patient 
records and special investigations. All information pertaining to named 
patients will be kept within the rules and norms of confidentiality at both the 
GF Jooste and Groote Schuur Hospitals and the service in general. Where 
data is reported on outside of this context, no reference will be made to the 
patient’s name or personal information. Only the study team will be aware of 
the full identity and clinical data of patients included in the study. Completed 
forms and case report material will be stored in a locked cabinet in a locked 
office. Where disclosure is necessary, such as where treatment or referrals 
are needed, patient’s consent will be sought. Any written or verbal reports or 
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presentations of this information will retain the patient’s anonymity. Third party 
information will also be held confidentially. As such, patients will not have 
direct access to their clinical records, but may, in consultation with the study 
team, have access to information regarding them.  
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Appendix 1: Schedule of measures 
Completed at screening (at primary care clinic)       
  Informed consent for Interview and MRI   ICF:IVMRI     
          
                    
  Beck Depression Inventory     BDI       
  The Alcohol Use Disorders Inventory    AUDIT       
  Substance Abuse and Mental Illness Screener SAMISS       
  Life Events Questionnaire of Brugha   LEQ       
  The Childhood Trauma Questionnaire   CTQ       
  Patient's Assessment of Own Functioning   PAOF       
  Activities of Daily Living     ADL       
                    
Completed at Visit #1: Interview and Neuromedical Assessment       
  Sociodemographic questionnaire           
  Neuropsychological test Battery             
   Prospective  and  
 Retrospective 
memory     
 PRMQ 
and 
MIST       
  ***Break***               
                    
  Miniature International Neuropsychiatic Interview plus MINI+       
  International HIV Dementia Rating Scale   IHDRS       
  The Neuropsychiatric Inventory      NPI       
  The UCT/GSH Neuromedical Assessment Form UNAF       
  Cape Town HIV Consortium risk behaviour scale RBS       
  Karnoksky Performance Scale     KPS       
  Camberwell Assessment of Need   CAN       
  Sheehan Disability Scale     SDS       
                    
              
 
  
      
        
  
Structural Diffusion Weighted Sequence 
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Appendix 2:  Summary score sheet 
 
Sticker:   
      
      
  
CD4  
  
J 
HIV-associated neurocognitive disorders study: Neuropsychological Test Summary Sheet 
Name 
 
Gender: M          F 
Date of examination (DD.MM.YYYY) Years of education: 
Date of birth (DD.MM.YYYY) 
 
Age: 
 
Examiner:      JL      JX      JJ Handedness: 
Examined in: English Xhosa 
 
    
A: Motor function       
A1: Successive Finger Taps Raw Score Mean SD 
D(sec): 
 
(              ) (              ) 
ND(sec): 
 
(              ) (              ) 
A2: Grooved pegboard 
   D(sec): 
 
(              ) (              ) 
ND(sec): 
 
(              ) (              ) 
    
B: Learning and memory       
B1: Hopkins Verbal Learning Test 
  
  Raw Score Mean SD 
Trial 1       
Trial 2       
Trial 3       
Total       
Learning       
DR                     (               %)     
Recognition: true positives 
 
Discrimination 
index    
false positive errors:     related (          )   unrelated (          )   
B2: Rey Complex Figure raw score mean SD 
Copy 
   
3 min recall 
   
delayed recall 
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B3: Brief Visuospatial Memory Test  
  Form   1    2    3    4    5    6  Raw Score T-score Percentile 
Trial 1 
   Trial 2 
   Trial 3 
   Total recall 
   Learning 
   Delayed recall 
   Percent retained 
   Recognition hits 
   Recognition false alarms 
   Recognition Discriminatin Index 
  Recognition response bias 
   
    
B: Learning and memory       
B4: Prospective Memory Test 
  
    
    
    
    
C: Attention       
C1: Mental alternation test 
   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Raw Score Mean 
ii.alphabet raw score                       s errors score 
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z mean                              s       
1  2  3  4   5   6   7   8   9  10 
11  12   13   14   15   16   
17      18   19   20   21   22   23    
A  B C D  E   F  G   H    I    J K    L   M     N     O    P    Q       R     S     T     U     V      W      
C2: WMS III Mental Control raw score                        SS  
 
C3: WMS III- spatial span Raw Scores (SS) 
  
Forward:                (             ) 
Backward             (             
) Total                     (                    ) 
    
D: Speed of processing 
Raw Score (Scaled 
Score)     
D1: WAIS III: Digit symbol coding (               ) 
 
D2: WAIS III: Symbol search (               ) 
 
    
E: Executive function       
E1: Trail-making  RS Percentile T-score SD 
Test A 
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E2: Color Trail-Making 
   
i.part 1 
   
ii.part 2 
   E3:Stroop Colour and Word 
Test expected residual  T (table IV) 
Word 
   
Colour 
   
colour word 
   
Interference 
   
E4: Wisconsin Card Sorting Test 
  Categories completed 
   Trials to first category 
   Failure to maintain set 
   Learning to learn 
   
    
F: Language       
G1: Category fluency test Raw Score Mean SD 
i.animals 
   
ii. Fruit and vegetables 
   
    
G: Intelligence       
WASI Raw score SS 
 Vocabulary test 
   Block design 
   Similarities 
   Matrix reasoning 
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ABSTRACT 
Infection with Human immunodeficiency virus (HIV) is associated with central nervous 
system (CNS) changes that may affect cerebral blood flow (CBF), metabolism, 
structure, and diffusion. Diffusion Tensor Imaging (DTI) is a neuroimaging technique 
offering unique insight into the neural mechanisms underlying HIV, as well as a potential 
means of monitoring disease progression and treatment response. The purpose of this 
review is to provide a review of experimental studies evaluating changes related to HIV 
with DTI 
 
INTRODUCTION 
Human immunodeficiency virus (HIV) is associated with a high prevalence of 
neuropsychiatric disorders, including depression, mania, anxiety and cognitive disorders 
(1). These problems contribute to the morbidity and mortality associated with HIV (1). 
While Highly active antiretroviral therapy (HAART )has been shown to be effective in 
reducing the incidence of severe HIV-associated neurocognitive disorders (HAND), 
evidence from functional Magnetic resonance imaging (fMRI) studies suggests that 
many will develop these disorders earlier than current treatment regimes would sanction 
initiation of treatment (2). It is also not known which individuals in the earlier phases of 
the disease will go on to develop HAND, nor who will respond to treatment (3).  
Preliminary evidence suggests that the neurotoxic effects of HIV results in damage to 
white matter tracts in the brain(4). Once damage is established and HAND ensue, the 
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ability of HAART to reverse existing dysfunction is probably limited (5).  Earlier treatment 
with HAART in at-risk or minimally symptomatic patients may prevent further decline in 
cognition and delay the course of HIV disease.  Identification of reliable early imaging 
correlates of risk for subsequent cognitive dysfunction, such early changes to white 
matter integrity, become all the more crucial to delineate. 
 
Nearly two-thirds of patients infected with HIV go on to develop neurologic involvement, 
including cognitive deterioration (1) Autopsy studies of HIV associated dementia (HAD) 
patients indicate prominent injury, including damage to the deep white matter(6). Studies 
of acute HIV infection suggest that virus enters the brain during acute infection but it is 
not clear whether virus that enters the brain during acute infection persists there for life 
or whether this is cleared by the host and HIV encephalopathy (HIVE) develops as a 
result of later introduction of new virus into the brain. It is crucial to understand the 
events that lead to establishment of virus in the brain and the eventual development of 
HIVE(6).  
On both Computed Tomography (CT) and structural Magnetic Resonance Imaging 
(sMRI), diffuse atrophy with ventricular dilatation (7) and white matter lesions have been 
noted to be associated with HAD. A correlation between declining cognitive function and 
the loss of volume in certain brain structures, including the basal ganglia and caudate 
nucleus, has also been reported (8). 
Dynamic contrast-enhanced MRI has identified sub-cortical grey and frontal white 
matter as the principal sites of early metabolic abnormalities (9) Both increased regional 
cerebral blood volume (rCBV) and post-contrast enhancement have been reported in 
the basal ganglia in moderate and advanced HAD, reflecting increased vascularity and 
blood-brain-barrier (BBB) permeability. These findings are consistent with the 
characteristics of the early neurological deficits, and the known predilection of HIV for 
the basal ganglia (10) The degree of neurocognitive impairment is correlated both with 
the degree of BBB breakdown in the basal ganglia and with viral load (11).  
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Both post mortem studies and a number of imaging studies in different modalities have 
established that HIV causes damage to the CNS, particularly to the subcortical regions 
and the frontal white matter.  In HIV infection, white matter changes are unreliably 
detected by sMRI.  Diffusion tensor imaging (DTI), an MRI method, is uniquely suited to 
the study of subtle white matter abnormalities. DTI studies have revealed CNS 
abnormalities in asymptomatic HIV positive patients with no cognitive impairment and 
normal structural MRI studies.  DTI can be used to quantify the magnitude and 
directionality of tissue water mobility (i.e. self-diffusion). Barriers, such as myelin 
sheaths, membranes, or white matter tracts, result in greater self-diffusion along the 
axis of the barrier and reduced diffusion out of the tract. This type of restricted self-
diffusion is termed ‘anisotropic.’ Fractional anisotropy (FA) is a measure derived from 
the diffusion tensor imaging that assesses the degree of anisotropic self-diffusion, that 
is,  the integrity of the white matter tract (12). The higher the FA (closer to 1) the healthier 
the tract, the lower FA (closer to 0) indicates damage to the integrity of the white matter 
tract. A second measure commonly reported in DTI is mean diffusion (MD), which 
measures the diffusion of water out of a tract.  The higher the MD (closer to 1), the 
greater the damage to the tract. FA indices from DTI measurements reflect the amount 
of coherently restricted diffusion (imposed by the presence of myelin) of free water. 
These coherently restricted diffusion pathways are most prominent in axonal bundles. 
DTI voxels are several orders of magnitude larger than cellular dimensions, so that the 
computed anisotropy indices reflect the cumulative effect of the underlying 
microstructure. While there is still controversy regarding the source of the anisotropy 
such as the contribution of the intracellular versus extracellular water to the diffusion 
signal(13), one can argue from a physical point of view that a reduced anisotropy can be 
the result of one of the following phenomenon: loss of myelin leading to reduced 
restricted diffusion, intact fibers but not coherently oriented and loss of fibers. Diffusion 
anisotropy thus carries microscopic (cellular level) anatomical information. However, the 
microscopic information is averaged over the large voxel volume. If there are multiple 
fiber populations with different fiber orientations, their contributions to the signal could 
be averaged. As a matter of fact, the cortex has low anisotropy (FA < 0.2), not because 
there are no fibers, but because axon and dendrite orientations are not normally aligned 
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within the large voxels in human cortex. If we can improve image resolution, we are 
likely to see higher anisotropy in the cortex. We observe diffusion anisotropy only when 
there are microscopic sources of diffusion anisotropy AND there is macroscopic 
homogeneity of the structures within a pixel. If we find changes in diffusion anisotropy, 
we cannot immediately conclude that the source of abnormalities lies in cellular level 
structures, such as myelin and axons; it could be due to the reorganization of axons at 
macroscopic levels. In summary DTI could provide us with information about the large-
scale networks that are made up of long tracts connecting distant relay stations in the 
brain. These networks are important for the development of higher brain functions such 
as language, praxis, social behavior and emotion. Lesions affecting white matter 
connections lead to dysfunction, and cognitive disorders are sometimes better 
explained by a disconnection mechanism between distant cerebral regions than by 
primary damage of those regions themselves(14). 
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Figure 1 
An example of DTI tractography.  Sagittal view. Different colors indicate different 
directions of the white matter tracts.  Green shows tract moving anterior-
posterior, blue shows superior-inferior and red shows left to right.  Tractography 
image was created on our Brainlab computer at CUBIC 
 
DTI has been used to identify age-related brain changes(15)and white matter alterations 
in a number of neurodegenerative disorders including Alzheimer's disease (16). Although 
loss of white matter is prominent in later stages of the neurodegenerative process, 
preliminary DTI studies in Alzheimer's disease found fractional anisotropy reduction in 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
vulnerable white matter regions even at preclinical stages. For example DTI of the 
corpus collosum and medial temporal lobe revealed that an increased genetic risk for 
developing Alzheimer disease (APOE epsilon4 carriers) is associated with reduced 
fractional anisotropy well before the onset of dementia (17).  
In this review, I will describe the known imaging and neuropathological correlates of HIV 
disease. Then novel MRI techniques such as diffusion tensor imaging will be discussed, 
with a view to elucidating how these techniques can be correlated with clinical and 
neuropsychological findings. Specific brain regions previously implicated in DTI studies 
will be explored, in order to develop hypotheses regarding which regions are likely to be 
affected in late stage HIV.  
 
METHODS 
 
Search strategy 
The search for studies was conducted using two approaches: 
1) Using a key word search of the following databases conducted on 12 March 2009- 
i) a. PUBMED: HIV [mh] OR Acquired Immunodeficiency Syndrome [mh] OR 
AIDS [tw] OR HIV [tw]) AND (DTI, Diffusion Tensor Imaging [mh]) AND 
(Cognition* Disorders [mh] OR memory [mh] OR memory* [tw] OR cognition 
[mh] OR cognition* [tw] OR AIDS Dementia Complex [mh] OR 
Neuropsychological Tests [mh]). We applied the following limits: Humans, 
Clinical Trial, Letter, and All Adult: 19+ years. 
 
ii) PsycINFO: HIV and DTI and Cognition 
 
2) Reviewing the reference sections of articles found in this way and searching for 
relevant publications. 
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Inclusion and exclusion criteria 
We included peer-reviewed published studies in which a clinical sample received a 
neuropsychological and/or neuromedical assessment in addition to DTI. A clear 
categorisation of EITHER a neurocognitive disorder OR of global/overall 
neuropsychological status in patients OR Centre for Disease Control (CDC) staging 
needed to be reported. Included studies were written in English and had experimental 
designs with adult human subjects with HIV. 
  
We excluded studies of children, or studies in which patients had acute medical illness 
(e.g. Tuberculosis), current HIV related neurologic disease (e.g. Tuberculosis 
meningitis), current DSM-IV Axis I diagnoses (depression) and current alcohol or 
substance abuse.   
 
 
Study sorting 
All articles retrieved on electronic search were loaded into a single Reference 
Manager™ database. Duplicates were removed. Using the criteria set out above, the 
database was reviewed to ascertain reliability of inclusion and exclusion. After this 
stage, 14 studies were identified and included. 
 
RESULTS 
Nature of studies 
The majority of studies identified were conducted in the USA, where clade B is 
predominant (n=13), with one being completed in Austria. Where reported, almost all 
studies were done in infectious diseases clinics, or in research projects that were 
associated with such clinics. Sample sizes of HIV positive individuals included in these 
studies ranged from 6 to 60. Most studies were cross-sectional, with only one study 
following up patients after one year. Most studies reported the range of CD4 cell count 
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and these ranged from a significant degree of immune suppression to CD4 counts of 
600+.  A summary of the studies is presented in table 1 
Measures 
The clinical assessment of neurocognitive disorders and white matter damage in HIV 
requires the exclusion of confounding causes. Most studies used psychiatric history or 
made use of rating scales to exclude participants who suffered from psychiatric 
disorders. Of those that used rating scales, one used the Centers for Epidemiology 
rating scale for Depression (CES-D), and one each used the Hamilton Depression 
Rating Scale. Patients with current psychiatric disorders are generally not included in 
studies of HAND. Many did not formally report on the screening of substance use 
disorders. Of those that did, used a combination of self-report and clinician-interview, 
with only one using formal drug testing procedures. Most utilized some type of 
standardized clinical or neurologic examination. Most did not report on of functional 
assessment. 
DTI measures 
FA and apparent diffusion coefficient or MD (ADC, equivalent to MD) were utilized in 
most of the studies to explore neurological dysfunction resulting from HIV infection 
(n=10). One used FA only, with another using MD alone.   DTI analysis using Statistical 
Parametric Mapping (SPM) was utilized in one recent study, while two have used fiber 
tracking and only one with axial and radial diffusion.  
White matter damage 
Diffuse damage to cerebral white matter is one of the most frequent neuropathological 
features of HIV-1 infection and was reported to be particularly prominent in the 
advanced stages of the disease. DTI abnormalities were most commonly reported in the 
frontal white matter (FWM), the corpus collosum, the internal capsule and the superior 
longitudinal fasiculus. 
 
Neuropsychological test batteries 
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In the studies included in this review, the neuropsychological test batteries varied 
widely. The prevalence of neurocognitive disorder was noted in 11 studies, with two 
utilizing the Memorial Sloane Kettering (MSK) score (1). Three utilized the American 
Academy of Neurology criteria (AAN) (18).  Three used a global deficit score and one a 
NPZ-8 score.  The MMSE was used to establish the presence or absence of dementia 
in 3 studies. The IHDS was utilized in one study 
Use of HAART 
A wide range of HAART regimens were reported. One did not mention whether the 
patients were receiving HAART. In five of the studies all of the patients were on HAART.  
A number of the studies did not mention which regimens the patients were receiving.  
One study assessed the effect of the CNS penetration of the HAART regimens on white 
matter integrity 
Quality of studies 
Most were high quality studies. One particular study was published as a brief report 
within a larger review of neuroimaging in HIV. What is striking is that most studies do 
not report on, or address all of those factors which might be considered to comprise a 
detailed and high quality study of the effects of HIV on white matter. For example, many 
did not report on any assessment of substance misuse and only one used urine tests to 
exclude substance use. One of the studies included participants with a previous history 
of substance abuse. Axis I diagnosis were often excluded on history only. In addition 
most of the studies did not formally report on functional assessment, which should be 
part of an assessment of neurocognitive dysfunction in HIV. One study included 11 
participants who tested antibody +ve for Hep C. It may be suggested that more formal 
reporting of this issues is needed to fully appreciate the role of HIV in causing loss of 
white matter integrity. 
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Table 1:  Summary of Literature review 
Subjects Major study findings Investigators Title 
10 HIV+ (viral 
load <400 to 
>400 K) 
All on HAART 
As viral load increased, 
anisotropy in the 
splenium and Genu 
decreased. Patients with 
greater viral loads had 
elevated diffusion 
constants in subcortical 
white matter. 
 
Filippi et al., 
2001(19) 
USA 
Diffusion tensor imaging 
of patients with HIV and 
normal-appearing white 
matter on MR images of 
the brain 
6 HIV+, 9 
controls. CD4 
mean=289 
 One patient not 
on HAART 
 
FA was decreased in 
the frontal lobes and 
increased in the internal 
capsule among HIV+ 
patients compared to 
controls. No group 
differences were found 
in mean diffusivity 
 
Polari et al., 
2001(20) 
USA 
White matter 
abnormalities in HIV-1 
infection: a diffusion 
tensor imaging study 
6 HIV+, 8 controls 
CD4 range 10–
187 
All on HAART 
 
Whole brain FA was 
decreased in HIV+ 
group, and significantly 
related to severity of 
dementia. Diffusion 
coefficient measures did 
not differ among groups. 
FA was decreased in all 
patient groups, 
indicating diffuse white 
matter disease. White 
matter abnormalities in 
asymptomatic patients 
may be detected before 
clinical findings. 
 
Ragin et al., 
2004(21) 
USA 
Whole brain diffusion 
tensor imaging in HIV-
associated cognitive 
impairment 
11 HIV 
seropositive 
The apparent diffusion 
coefficient (ADC) was 
Cloak et al., 
2004(22) 
Increased frontal white 
matter diffusion is 
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patients were 
compared to 14 
seronegative 
subjects 
Mean CD4 191 
 
6 patients on 
HAART 
significantly increased in 
the HIV patients, 
primarily in the frontal 
white matter 
USA associated with glial 
metabolites and 
psychomotor slowing in 
HIV 
25 HIV+ (normal 
cognitive, MCMD, 
HAD) 
 
FA was decreased in all 
patient groups, 
indicating diffuse white 
matter disease. White 
matter abnormalities in 
asymptomatic patients 
may be detected before 
clinical findings. 
 
Hall et al., 
2004(8) 
USA 
Neuroimaging in HIV 
infection 
11HIV+ and 11 
controls 
CD4 24-427 
All on HAART 
Lower FA values 
correlated with specific 
cognitive deficits in the 
putamen, caudate and 
centrum semiovale 
 
Ragin et al., 
2005(23) 
USA 
Diffusion tensor imaging 
of subcortical brain injury 
in patients infected with 
human immunodeficiency 
virus.   
60 HIV + patients 
and 30 controls 
Compared 
CD4<250 to 
CD4>250 
HAART not 
mentioned 
reduction in FA in the 
frontal white matter, 
corpus callosum and 
hippocampus of HIV 
positive individuals 
compared to controls 
 
No difference between  
the high and low CD4 
count groups  
 
Thurnher et 
al 2005(24) 
Austria 
Diffusion-Tensor Imaging 
of the brain in Human 
Immunodeficeincy virus-
positive patients.   
11 HIV and 11 
control 
participants 
CD4 ranged from 
24 to 427 
FA values for the 
splenium were 
significantly reduced in 
the patients infected 
with HIV and correlated 
with dementia severity 
and deficits in motor 
speed 
Wu et al., 
2006(25) 
USA 
Diffusion Alterations in 
Corpus Callosum of 
Patients with HIV 
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On HAART for 
5yrs  
30 HIV + and  30 
seronegative 
controls 
Mean CD4 612 
13 on HAART 
MD increases in normal 
appearing white matter 
in the +ve group 
Stebbins et 
al., 2007(26) 
USA 
HIV-associated 
alterations in normal-
appearing white matter: a 
voxel-wise diffusion 
tensor imaging study 
39 HIV + and 32 
seronegative 
controls 
Mean CD4 -461 
Some on HAART 
After one year +ve 
group showed greater 
increase in MD in frontal 
and parietal white matter 
and Genu than 
seronegative controls 
Chang et al 
2008(27) 
USA 
Greater than age-related 
changes in brain diffusion 
of HIV patients after 1 
year 
21 HIV-1 infected 
and 19 healthy 
control men and 
women 
Poorer fiber integrity of 
the corpus callosum in 
HIV-1 than controls that 
was more pronounced in 
posterior than anterior 
regions.  component 
processes of 
Visuospatial perception 
are compromised in 
HIV-1 infection 
attributable, at least in 
part, to degraded 
callosal microstructural 
integrity 
Muller-
Oehring et al 
2009(28) 
USA 
Callosal Degradation in 
HIV-1 Infection Predicts 
Hierarchical Perception: 
A DTI study 
39 HIV-infected 
individuals (49% 
with acquired 
immunodeficiency 
syndrome [AIDS]; 
mean CD4 = 529) 
and 25 
Cognitive impairment in 
the HIV-infected group 
was related to white 
matter injury in the 
internal capsule, corpus 
callosum, and superior 
longitudinal fasciculus. 
Gongvatana 
et al 2009(29) 
USA 
White matter tract injury 
and cognitive impairment 
in human 
immunodeficiency virus-
infected individuals 
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seronegative 
subjects. 
On HAART 
29 men and 13 
women with HIV 
infection and 88 
healthy, age-
matched controls 
Some on HAART 
Patients without 
dementia 
Unmedicated patients 
had notably high 
transverse diffusivity, 
indicative of myelin 
compromise, in the 
occipital forceps, inferior 
cingulate bundle, and 
superior longitudinal 
fasciculus. 
Pfefferbaum 
et al 2009(30) 
USA 
Frontostriatal fiber bundle 
compromise in HIV 
infection without 
dementia. 
18 healthy 
controls, 21 HND 
and 8 HAD 
patients. 
18 on HAART 
HAD patients exhibited 
significantly elevated 
MD and RD (radial 
diffusion) in the parietal 
white matter when 
compared to HND 
patients.  RD was 
affected to a much 
greater extent than AD 
(axial diffusion) by HIV 
infection, which may 
suggest that 
demyelination is the 
prominent disease 
progression in white 
matter. 
Chen et al 
2009(31) 
USA 
 
 
White matter 
abnormalities revealed by 
diffusion tensor imaging 
in non-demented and 
demented HIV+ patients 
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DISSCUSSION 
 
Studies have used DTI to explore the integrity and orientation of brain tissue in vivo by 
measuring tissue water diffusion. These studies have measured fractional anisotropy 
(FA), considered to be an index of white matter integrity, by either using a region of 
interest analysis or by exploring whole brain differences in FA and MD with voxel-based 
analysis.  More recent work has used tractography or radial and axial diffusion.  DTI 
tractography can delineate the core of large white matter tracts and is expected to be a 
powerful tool to investigate white matter anatomy and disease in situ(32).  FA and MD 
have been utilized to explore neurological dysfunction resulting from HIV infection. 
Studies included in this review have reported that white matter damage in the CNS in 
HIV correlates with severity of disease and cognitive impairment. These studies also 
suggest that damage to white matter tracts can occur early in the disease process in 
HIV and that some of this damage may be modified by HAART.  In fact white matter 
abnormalities in asymptomatic patients may be detected before clinical findings. 
 A correlation between disease burden markers such as  increased viral load and 
reduction of FA in the splenium and Genu of the corpus callosum has been found in HIV 
infected subjects(19). FA has been found to be decreased in white matter of the frontal 
lobes, corpus collosum and the internal capsule in non-demented HIV+ patients when 
compared to age-matched controls(20, 24). Based on their results Wu el al 2006 
suggested the in vivo assessment of callosal integrity, using neuroimaging as a 
potential biomarker of brain injury in patients infected with HIV(25).  Formulations of 
callosal function emphasize multiple routes for transfer of information between 
hemispheres. Injury may be reflected in slowed response initiation and longer reaction 
times on tasks involving hemispheric transfer or integration between regions. 
A whole-brain DTI histogram analysis demonstrated that a reduction of the mean FA 
was significantly associated with the severity of dementia(21).   DTI measures in the sub-
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cortical regions have been significantly correlated with a loss of function in specific 
cognitive domains(21, 23). Increased frontal white matter ADC has been associated with 
increased glial metabolites in HIV-infected subjects when compared to seronegative 
subjects. ADC was correlated positively with the glial marker myoinositol, suggesting 
that the increased brain water diffusion may reflect increased glial activation or 
inflammation(22). However a study with regions of interest (ROIs) placed in the splenium 
and Genu of the corpus callosum, frontal white matter, and hippocampus in patients 
grouped with the viral loads and CD4 counts, reported significantly reduced FA and 
increased ADC only in Genu of HIV+ patients and no statistically significant correlation 
existed between FA (and ADC) values and CD4 counts(24). More recently, voxel-based 
DTI analysis using Statistical Parametric Mapping (SPM) has demonstrated significantly 
increased MD in the seropositive population when compared to seronegative subjects 
(26).  A prospective DTI study showed that after one year the HIV+ve group showed a 
greater increase in MD in frontal and parietal white matter and Genu than seronegative 
controls(27).   
Unmedicated patients were shown to have notably high transverse diffusivity, indicative 
of myelin compromise, in the occipital forceps, inferior cingulate bundle, and superior 
longitudinal fasciculus compared to those receiving HAART(33).  However a recent study 
found that white matter injury was not found to be associated with estimated CNS 
penetration of antiretroviral(29). 
While these reported findings clearly demonstrate the potential clinical utility of DTI in 
discerning white matter abnormalities resulting from HIV viral infection, most of the 
studies to date have only focused on comparing HIV+ patients with healthy controls in 
predominantly Clade B regions. To our knowledge there have been no investigations of 
how white matter abnormalities may be associated with a range of HAND in HIV+ 
populations or the effect of Clade C on white matter.  
The development of a neuroimaging biomarker for early CNS disease in HIV positive 
patients, may allow for the earliest possible detection of cognitive impairment.  The 
principal advantage of DTI is quantitative sensitivity to changes that may not be 
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detected with conventional T1-, T2-weighted magnetic resonance imaging (MRI). 
Postmortem studies have found that conventional MR imaging is insensitive to 
microscopic brain injury in HIV patients (34) 
I hypothesize that: 
(1) White matter damage as measured by alterations in FA and MD using DTI will be 
found in HIV positive subjects infected with Clade C HIV 
(2) Both FA and MD will correlate with severity of HAND 
(3)Poor Prospective memory will be correlated with decreased FA in HIV positive 
patients. 
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ABSTRACT 
The relationship between cognitive impairment and white matter integrity in human 
immunodeficiency virus (HIV) remains poorly understood, particularly in clade C.  We 
utilized diffusion tensor imaging (DTI) and a comprehensive neuropsychological 
evaluation to investigate the relationship between cognitive impairment and white matter 
integrity in HIV-positive subjects with clade C HIV. 44 HIV-infected individuals and 10 
seronegative subjects were compared using a voxel-based approach to define fractional 
anisotrophy (FA) and mean diffusion (MD). Compared to healthy controls the HIV-
infected group exhibited decreased FA in the corpus callosum, superior longitudinal 
fasiculus, cingulum and sagittal stratum.  Within the HIV group, those with HIV 
associated Dementia (HAD) (n=14) had more widespread damage, including deceased 
FA in the inferior frontal occipital fasiculus. Poor performance in executive function in 
the HIV-infected group was associated with reduced white matter integrity in the sagittal 
stratum. Abnormalities in MD were seen in both early and late dementia. Compared with 
HIV negative controls, HIV patients with no cognitive impairment had white matter 
changes (decreased FA and increased MD).  White matter changes precede cognitive 
changes, and although there are few associations between changes in FA/MD and 
neuropsychological impairment, white matter changes were more widespread in more 
severely cognitively impaired patients. This study provides evidence that white matter 
integrity is compromised in individuals infected with clade C HIV.   
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INTRODUCTION 
HIV-associated neurocognitive disorders (HAND) remain important even in the era of 
highly active antiretroviral therapy (HAART). Although a decline has been noted in the 
incidence of HIV-associated dementia (HAD) in the developed world since the roll out of 
HAART, HIV associated neurocognitive disorders (HAND) remain prevalent (1).  
Despite the relative efficacy of HAART in controlling HIV disease, there is no treatment 
which specifically targets the cause of HAD nor which prevents neuronal damage 
caused by the virus.  Although first recognized two decades ago as a subacute, 
subcortical dementia, the clinical syndrome has evolved, in part due to the use of 
antiretroviral drugs(2). In South Africa the roll out of HAART has not reached levels 
seen in the developing world. 
 
Early studies suggested that individuals infected with clade C may be less likely to 
develop cognitive impairments due to a biological defect in the tat protein present in 
clade C (3).  However in recently published data from India, it was shown that 
individuals infected with clade C exhibit significant cognitive impairment, suggesting that 
the brain is, in fact, vulnerable among individuals with clade C HIV(4).  These findings 
are notable because clade C is the most common form of HIV in the world, as well as 
the dominant strain in South Africa (5).  In support of this, a study using the HIV 
Dementia scale (HDS) reported HAND in 23, 5% of patients attending HIV clinics in 
South Africa(6) 
Although much work has been done to elucidate the complex mechanisms underlying 
HIV associated neurotoxicity, the relationship between cognitive impairment and white 
matter integrity in HIV remains incompletely understood.   This is particularly the case 
for the genetic form of HIV known as clade C, since nearly all studies of cognitive 
function in HIV have been conducted in North America where the dominant genetic 
strain of the virus is clade B. Autopsy studies of HAD  patients indicate prominent injury, 
including damage to the deep white matter (7)  A range of neuroimaging modalities 
have been used to study the relationship between white matter damage and 
neuropsychological impairment, which has identified subcortical grey and frontal white 
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matter as the principal sites of early abnormalities (8). HAD is associated with diffuse 
atrophy with ventricular dilatation (9) and white matter lesions . A correlation between 
impaired cognitive function and the loss of volume in certain brain structures, including 
the basal ganglia and caudate nucleus, has also been reported (10). These findings are 
consistent with the characteristics of the early neurological deficits, and the known 
predilection of HIV for the basal ganglia (11).   
There are limitations to these methods.  In HIV infection white matter changes are 
unreliably detected by structural Magnetic Resonance Imaging (sMRI). Fortunately, 
diffusion tensor imaging (DTI), which quantifies the magnitude and directionality of 
tissue water mobility, is able to provide information about the micro structural integrity of 
the white matter.  DTI provides two indices, fractional anisotropy (FA), which reflects the 
orientation specificity of water diffusion, and which is lower when white matter damage 
is present and mean diffusivity (MD), which reflects the degree of water diffusion within 
an imaging voxel, and which is higher when white matter damage is present (12). DTI 
studies in HIV have shown diffuse damage to cerebral white matter (i.e., decreased FA 
or increased MD) and these effects have been found to be particularly prominent in the 
advanced stages of the disease Studies conducted in countries where clade B is 
predominant have reported subcortical white matter injury mainly in the regions of the 
corpus callosum,  frontal lobes and internal capsule (13-15) .  Furthermore, diffusion 
abnormalities in the corpus callosum in HIV patients have been associated with 
dementia severity and motor speed losses(16). 
The present study examined the relationship of DTI indices to global neurocognitive 
impairment among HAART naïve patients infected with clade C HIV.  We hypothesized 
that (i) Clade C HIV infection would be associated with reduced white matter integrity in 
the regions of the corpus callosum, frontal lobes and internal capsule; (ii) that more 
white matter injury would be evident among individuals with HAD. 
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METHODS 
 
Subjects  
Participants (n=46) with HIV and healthy non-HIV controls (n=10), aged 18-35 years 
were recruited from the Infectious Diseases Clinics within the Groote Schuur Hospital 
recruitment area. To be eligible HIV participants were required to have a positive 
diagnosis of HIV infection made within the last six months (based on serologic testing by 
ELISA and Western blot), and have not previously used anti-retroviral medications 
(“HAART naïve”) In addition, patients were required to have at least 7 years of formal 
education.   
Patients were excluded if they were 1) using psychotropic medication, 2) had a recent 
(6 month) substance abuse history as defined by responses to the Alcohol Use 
Disorders Inventory (AUDIT) and the Substance Abuse and Mental Illness Screener 
(SAMISS) 3) had a score greater than 16 on the Beck Depression Inventory (II), 4) had 
other current DSM-IV disorders as determined by the MINI , or 5) a lifetime history of 
head injury with loss of consciousness exceeding 30 minutes.  
 
Procedure 
Participants completed clinical assessments in a single testing session. Neuroimaging 
was conducted within one week of the initial evaluation. All measures were administered 
and scored according to standard procedures. Written informed consent was obtained 
prior to enrollment and exposure to any study related procedure. The protocol was 
approved by the Committee for Human Research of the University of Cape Town.   
A neuropsychological test battery (Table 1) was administered to all participants to 
assess specific domains of attention, concentration, learning, memory psychomotor 
speed and executive function. The battery was based on that used by the HIV 
Neurobehavioral Research Centre(17), and included tests were adapted in discussion 
with three local neuropsychologists. Changes to word lists to reflect local language and 
idiom were made. All instruments had their instructions and content translated into 
isiXhosa and Afrikaans- instructions were also back-translated for fidelity.  A full 
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neuromedical examination was conducted on all participants. Blood for CD4 cell counts 
was taken in the infectious diseases clinic.  
Table 1: Neuropsychological test Battery 
Domain Test 
A: Motor function Successive Finger Taps, Grooved 
pegboard 
B: Learning and memory Hopkins Verbal Learning Test, Rey 
Complex Figure, Brief Visuospatial 
Memory Test (BVMT) 
C: Attention Mental alternation test, WMS III Mental 
Control, WMS III- spatial span 
D: Speed of processing WAIS III: Digit symbol coding, WAIS III: 
Symbol search 
E: Executive function Trail-making test A(TMTA), Colour trails 
part 1 and 2, Stroop Colour and Word test, 
Wisconsin Card Sorting Test 
F: Language Category fluency test i) animals ii) fruit and 
vegetables 
G: Intelligence WASI 
 
Determination of dementia  
The neuropsychological test battery, together with scores from a neuromedical 
assessment and reported functional assessment was used to classify participants into 
one of four HAND categories, based on the updated American Academy of Neurology 
criteria (18): no impairment, asymptomatic neuropsychological impairment (ANI), mild 
neurocognitive disorder (MND) and HIV-associated dementia (HIV-D). Using the 
modified AAN classification, participants who scored >2 SD below the z-score cut-offs 
on at least two domains of function was rated NP2; those who scored between 1.0 and 
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2 SD on two domains of function, or >2 SD and 1-2 SD, were rated NP1. In order to 
allow for comparability with other studies, we also categorized participants into the 
corresponding Memorial Sloan Kettering (MSK) scores. An MSK severity score of 0 
represents no cognitive impairment, 0.5 represents mild cognitive impairment not 
sufficient to meet criteria for dementia, and a score of 1.0 represents dementia(19). The 
final classification was conducted by a consensus panel comprising two HIV 
neuropsychiatrists (JJ, JH) and an experienced neurologist (MC).    
Data from 51 HIV negative controls were used to generate Z-scores for establishing 
local norms.  
  
Brain Imaging 
Imaging was performed on a Siemens Magnetom 3T Allegra within 7 days of the 
screening and neuropsychological assessment. We acquired a multi-directional 
diffusion weighted sequence with 30 diffusion directions, 1 b=0 sec/mm2 direction, 
TR=8800 ms, TE=88 ms and a b-value=1000 sec/mm2. The images were acquired as a 
mosaic resulting in a 960 x 960 matrix with 60 slices per volume, and a corresponding 
in-plane spatial resolution and slice thickness of 2 x 2 mm2 and 2.2 mm, respectively. 
The 2.30 minute sequence was repeated three times and averages were derived.  
 
Image processing 
Eddy current correction was performed separately in each of the three acquisitions 
using affine transformations in FSL (Oxford Center for MRI of the Brain, Oxford, UK).  
The data were then imported to MATLAB (The Mathworks Inc, Natick, MA) for further 
processing. Co registration was performed across the three acquisitions using affine 
transformations with the unweighted image of the first average as a reference. For each 
of the three acquisitions, diffusion tensors were calculated and outliers were rejected by 
first calculating Z-scores based on 25 and 75 percentile limits, and then discarding data 
points more than 3 standard deviations away from the mean. The three acquisitions 
were then averaged and mean diffusivity (MD) maps were calculated. Diffusion tensors 
and fractional anisotropy (FA) images were then derived. An affine as well as a non-
linear registration of the B0 images to each subject’s structural T1 image (intra-subject) 
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was performed. The warps were applied to the FA images. A mean FA template was 
then created from all the subjects followed by a final registration and warp of all the FA 
images to the mean template. The same registration transforms were applied to the MD 
images. DTI analysis based on voxel-based morphometry methods was performed 
group-wise for every voxel. And this was true for each t-test comparison (ie Controls vs 
Dementia, Controls vs NAD etc.).A general linear model ANOVA was performed on the 
FA and MD voxels of each cohort to determine significant differences between the 
groups. This was performed at a p<0.01uncorrected threshold with a FA mask of 0.25.   
Significant clusters were defined by the analysis (p < 0.01). Mean FA and MD values for 
each significant voxel cluster was calculated and tabulated. A DTI white-matter atlas 
(reference Mori et al. 2005, MRI atlas of human white matter, published 2005 by 
Elsevier, authors are Susumu Mori, Setsu Wakana, Lidia M. Nagae-Poetscher and 
Peter C.M van Zijl from John Hopkins University) was used to determine the anatomical 
locations by manually inspecting and comparing the mean FA color map with the atlas 
labels. 
 
Statistical analysis 
Multivariate tests of overall differences between HIV-positive groups and healthy 
seronegative control (HC) group were conducted for motor function, learning and 
memory, attention, speed of processing or executive function domains. Additionally, 
three linear regression models were created to determine the independent associations 
between the individual neuropsychiatric tests and FA values in the regions of the CC 
rostrum, sagittal stratum and the cingulum. Years of education was controlled for in all 
analyses, as it was significantly different between cases and controls.  Age and gender 
were not significantly different between cases and controls. 
Contrasts between HIV-positive groups (0, 0.5 and 1) and the healthy seronegative 
control (HC) group were then drawn to examine the associations between HIV infection, 
cognitive impairment and white matter FA. Whole brain voxel analysis of FA and MD in 
the HC group was also compared to the subgroups of HIV+ (no cognitive impairment, 
mild cognitive impairment and dementia).  Protection from type I error was maintained 
by lowering the p-value to p <0.01. 
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RESULTS 
Of the 56 subjects originally enrolled, 54 participants (HIV+ n=44 and seronegative 
controls n=10) were included in the final analysis. The imaging data from two subjects in 
the HIV group were discarded due to movement artifacts. The mean age of the HIV+ 
participants and the control group was 29.1 (SD3.61) and 25.8 years (SD 4.78) 
respectively (see Table 2).  At 11.6 years the average level of education of the 
seronegative control cohort was higher than the HIV cohort (p=0.0287).  The mean CD4 
count of the HIV positive group was 331.   
Table 2: Demographic characteristics of sample 
 Seronegative 
Controls 
Means(SD) 
HIV+ 
Means(SD) 
T-test 
2 tailed, unequal 
variance 
Gender   P=0.1174 
Age 25.8(4.78) 29.08(3.61) P=0.06 
Level of education 11.55(2.13) 9.63(1.85) P=0.0287 
 
The multivariate test of overall differences among groups were not statistically 
significant for the motor function, learning and memory, attention, speed of processing 
or executive function domains, when controlling for years of education completed.  
DTI 
Individual FA values were found to be significantly lower in HIV+ patients in the corpus 
callosum (CC) rostrum (p=<.001) the sagittal stratum (p=<.001) and the cingulum 
(p=0.003) compared to healthy controls. Other comparisons to the seronegative controls 
were made using a NAD group (n=4), a group with mild cognitive impairment (n=26) 
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and a HAD group (n=14).  A final comparison was made between those with HAD and 
the rest of the HIV cohort.   The FA results are summarized in Table 3.   
 
     
Table 3:  Summary of FA results 
Analysis Anatomy Hemisphere Fractional 
anisotropy 
P value Mean FA 
Control vs. 
NAD 
 
Superior 
longitudinal 
fasciculus 
Left Decrease 
in FA 
p = 
0.002 
Control - 
0.425 
(0.035) 
NAD - 0.376 
(0.033)  
 
 Sagittal stratum Left Decrease 
in FA 
p = 
0.001 
Control – 
0.411(0.081)  
NAD – 
0.482 
(0.077)   
 Inferior fronto-
occipital fasciculus 
Right Decrease 
in FA 
p = 
0.003 
Control – 
0.391(0.058) 
NAD – 
0.323 
(0.049) 
 Inferior longitudinal 
fasciculus 
Right Decrease 
in FA 
p = 
0.003 
Control – 
0.409 (0.07) 
NAD – 
0.320 (0.07) 
Control vs. 
mild cog 
impairment 
 
Superior corona 
radiata 
Right Decrease 
in FA 
p = 
0.0039 
Control – 
0.377 (0.05) 
Mild – 0.330 
(0.051) 
 
 Anterior thalamic Left Decrease p = Control – 
0.329 
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radiation in FA 0.0025 (0.039) 
Mild – 0.280 
(0.04) 
 Posterior limb of 
internal capsule 
Right Decrease 
in FA 
p = 
0.0076 
Control – 
0.401 
(0.091) 
Mild – 0.370 
(0.084) 
 Genu of the corpus 
callosum 
Bilateral Decrease 
in FA 
p = 
0.0072 
Control – 
0.452 
(0.106) 
Mild – 0.361 
(0.094) 
 Inferior longitudinal 
fasciculus 
Bilateral Decrease 
in FA 
p = 
0.0034 
Control – 
0.379 
(0.067) 
Mild – 0.312 
(0.06) 
Control vs. 
HAD 
Genu of the corpus 
collosum 
Bilateral Decrease 
in FA 
p = 
0.007 
Control – 
0.382 
(0.073) 
Dementia – 
0.299 
(0.053) 
Control vs. 
HIV 
CC rostrum 
 
Bilateral  Decrease 
in FA 
p = 
0.003 
Control – 
0.423 
(0.105) 
HIV – 0.347 
(0.0894) 
 Superior 
longitudinal 
fasciculus 
Left Decrease 
in FA 
p = 
0.005 
Control – 
0.394 
(0.0328) 
HIV – 0.343 
(0.0319) 
 Sagittal stratum Left Decrease p = Control – 
0.395 
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in FA 0.001 (0.0845) 
HIV – 0.336 
(0.0805) 
 Cingulum Right Decrease 
in FA 
p = 
0.007 
Control – 
0.522 
(0.0427) 
HIV – 0.457 
(0.0270) 
HIV vs. 
HAD 
Inferior frontal 
occipital fasciculus 
Right Decrease 
in FA 
p = 
0.003 
HIV – 0.352 
(0.037) 
HAD – 
0.308 
(0.031) 
 Superior 
longitudinal 
fasciculus/Posterior 
limb of internal 
capsule 
Bilateral Increase in 
FA 
p = 
0.0007 
HIV – 0.360 
(0.085) 
HAD – 
0.403 (0.09) 
 
Three linear regression models were created to determine the independent associations 
between the individual neuropsychiatric tests and FA values in the regions of the CC 
rostrum, sagittal stratum and the cingulum. The overall model predicting FA values in 
the sagittal stratum was significant, F (13, 26) =-2.29, p=0.04, adjusted R2 = .30. 
Increased impairment in Colourtrails 1 (b = -.36, t = 2.16, p =.040), was a significant 
predictor of lower FA scores in the sagittal stratum region. Although the overall model 
predicting FA values in the cingulum region was statistically significant (F (13, 26) = 
2.75, p < .014, adjusted R2 = .0.67), only lower level of education was a significant 
predictor of lower FA scores (b = -0.46, t = 2.73, p =.011).  
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 Fig. 1 Axial view: Control cohort vs. HIV dementia cohort. The blue blobs indicate a FA 
decrease in the genu of the corpus callosum in the dementia group when compared to 
controls. Cluster threshold = 10 voxels and p < 0.01.  
 
 Fig. 2 Sagittal view: Control cohort vs. HIV cohort. The blue blobs indicate an FA 
decrease in the sagittal stratum of the HIV cohort compared to controls. Cluster 
threshold = 10 voxels and p < 0.01. 
The same group comparisons were made measuring MD (see table 4).  No significant 
differences were found between controls and HIV+participants, or between controls and 
those with mild cognitive impairment.  However, significant increases in MD were found 
in the HIV+ group with no cognitive impairment and the dementia group when compared 
to the control group.  This may suggest that inflammation is greatest in the very early 
and late stages of HAD (a biphasic inflammatory model). When comparing patients with 
HAD to the rest of the HIV cohort MD was increased in the inferior fronto-occipital 
fasiculus.    
 
Table 4:  Summary of MD results 
 
Analysis 
Anatomy Hemisphere Mean 
diffusion 
Significance 
value 
Control vs. 
NAD 
Superior 
longitudinal 
fasciculus 
Right Increase in MD p = 0.00085 
 Internal 
capsule 
Right Increase in MD p = 0.0024 
 Anterior 
thalamic 
radiation 
Left Increase in MD p = 0.0013 
 Splenium of Right Increase in MD p = 0.0016 
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corpus 
callosum 
Control vs. 
HAD 
Superior 
longitudinal 
fasciculus 
Left Increase in MD p = 0.00045 
 Inferior fronto-
occipital 
fasciculus 
Right Increase in MD p = 0.00044 
 Cingulum 
(hippocampus) 
Bilateral Increase in MD p = 0.0012 
 
HIV vs. HAD Inferior fronto-
occipital 
fasciculus 
Right Increase in MD p = 0.0019 
 
 
Fig. 3 Coronal view: Control cohort vs. NAD cohort. The orange blobs indicate an 
increase in mean diffusion of the NAD cohort compared to controls in the internal 
capsule. Cluster threshold = 10 voxels and p < 0.01. 
 
DISCUSSION 
This study confirms that DTI-detected micro structural white matter abnormalities are 
present in clade C HIV when compared with healthy controls. These changes were 
more extensive in those with HAD. These include MD and FA changes in the inferior 
fronto-occipital fasiculus. We were able to detect white matter abnormalities in 
cognitively normal individuals and HIV+ participants with mild cognitive impairment, 
suggesting loss to white matter integrity early in the disease process.  Although the 
overall model of neuropsychological tests predicted lower FA in the sagittal stratum and 
cingulum, there were few associations between individual neuropsychological tests and 
lower FA in the regions identified.  Increased MD detected in the cognitively normal 
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(NAD) group and they HAD groups only, suggests a biphasic inflammatory process in 
HIV dementia.   
Our study indicates that, in keeping with previous work in Clade B, individuals infected 
with clade C HIV have white matter abnormalities. The white matter damage has been 
found to be more prevalent and severe in patients with HIV-1 associated dementia (20).  
Consistent with a previous DTI study we demonstrated preferential injury to the corona 
radiate, corpus callosum and superior and inferior longitudinal fasiculus (21).  
Involvement of the corpus callosum in HIV encephalitis has been reported in 
postmortem findings (22).  A number of DTI studies in HIV have reported white matter 
damage to the corpus callosum (23-25).    
 We found that HIV+ individuals without HAND also demonstrated white matter 
changes. Thus HIV related neurotoxicity occurs in the absence of clinical features of 
cognitive impairment. DTI abnormalities have previously been reported in the FWM of 
cognitively asymptomatic HIV+ patients with normal structural MR studies (13)..  
We also found increases in FA and MD in the HAD group when compared to the rest of 
the HIV cohort in the superior longitudinal fasiculus. The standard interpretation of these 
results are that increased FA in the areas represent increased white matter integrity in 
HAD participants compared to participants with mild cognitive impairment.  However 
Stebbins et al (26) found similar increases in FA and suggested that increased FA could 
be due to loss of the complexity of the white matter matrix in those regions.  If a voxel 
contains only parallel white matter fibers, FA can be high.  Damage to the matrix would 
result in loss of crossing and non-parallel fibers with sparing of the parallel fibers and a 
paradoxical increase in FA.  One indicator of such a process would be an increased 
MD, which suggests general tissue damage, together with the increased FA (27).  This 
relationship is seen in the superior longitudinal fasiculus in this study.  
Colour trails 1 predicted reduced FA in the sagittal stratum, suggesting that this 
neuropsychological test may be sensitive to white matter damage in clade C HIV.  It is 
possible that this may be a clade-specific difference, wherein we found that HIV positive 
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participants performed as well as HIV negative controls on the grooved pegboard test, a 
measure consistently used to ascertain whether HIV associated subcortical 
neuropathology exists (28, 29). Previous DTI studies in clade B found correlations 
between motor speed losses and poor white matter integrity of the corpus callosum(30)  
Data from Alzheimer’s research show that data show that maximal immunoreactivity in 
neurons occurs during the early disease stages prior to the maximal activation of 
astrocytes and microglia (31) and very late stages of the disease.  The increases in MD 
which we detected follow a similar biphasic pattern. 
The neurocognitive impact of the clade C HIV has not been determined. A study in 
southern India among individuals with the clade C virus with advanced HIV.  The results 
suggested that cognitive difficulties are present among individuals with the clade C virus 
in India, with more than half of the patients with advanced HIV meeting the criterion for 
impairment in two cognitive domains(32).However investigation of the  
neuropathogenesis induced by HIV-1 clades using an animal model, revealed greater 
astrogliosis and increased loss of neuronal network integrity and an increased number 
of memory errors in clade B compared to clade C(33).  Additional study is needed to 
determine if clade C HIV infection is more or less prone to cause neurocognitive deficit 
than the clade B virus. Furthermore, the impact of antiretroviral therapy on 
neurocognitive dysfunction in clade C viral infection needs to be determined. 
Limitations of our study include the relatively small samples, and the cross sectional 
design.  Previous reviews of cross-cultural influences on neuropsychological testing in 
South Africa indicate that normative studies should take account of the influential 
variable of quality of education, in addition to level of education. (34). Normative 
neuropsychological data was generated for this study from 51 individuals from the same 
socio-economic group, however level of education was higher in the control group.   The 
data here are not able to address the question of whether white matter changes noted 
in the asymptomatic and mild cognitive disorder groups represent an early marker of 
subsequent cognitive decline.   
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Despite these limitations, findings here revealed lower FA and increased MD in the HIV 
positive groups in the corpus callosum, and other regions.  Future work could usefully 
focus on anisotropy measurements as quantitative imaging biomarker in the setting of 
HANDs using larger longitudinal studies.  Identification of a reliable early imaging 
correlates of risk for subsequent cognitive dysfunction, such early changes to white 
matter integrity, may allow for earlier treatment with HAART and delay the course of HIV 
disease.  Studies examining response to HAART treatment in patients infected with HIV 
will be important to determine whether DTI abnormalities observed in the corpus 
callosum and other regions reflect reversible or more advanced irreversible injury. 
Correlates of white matter damage and neurocognitive decline need to be sought, 
including whether measures of central viral load correlate with poor FA values, illness 
duration, age, treatment exposure and treatment adherence. These factors are almost 
certainly critical in determining the overall impact of HIV on brain function, and in 
particular on white matter integrity.  In the interim these findings point to the potential 
value of FA and MD as a measure of central nervous system damage in HIV positive 
patients. 
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ABTRACT 
HIV-associated prospective memory (ProM) impairment has emerged as a significant 
predictor of medication management and independence in actives of daily living. The 
relationship between ProM and white matter integrity in HIV has not previously been 
investigated.  Participants including 128 HIV-infected individuals and 32 seronegative 
subjects were assessed using a comprehensive neuropsychological evaluation and 
both objective and subjective measures of ProM. We utilized diffusion tensor imaging 
(DTI) to investigate the relationship of white matter integrity to ProM in 37 HIV-positive 
subjects using a voxel-based approach to define fractional anisotrophy (FA) and mean 
diffusion (MD). Compared to healthy controls the HIV-infected group experienced 
difficulty with the complex cognitive processes involved in ProM. Poor ProM correlated 
with performance on neuropsychological tests of executive functioning, information 
processing speed, learning, and working memory and retention or semantic memory. 
The prospective retrospective memory questionnaire (PRMQ) did not correlate with 
objectively measured ProM.  The study also provides evidence that CNS injury is 
evident among individuals with poor ProM infected with HIV. Those with poor ProM had 
significantly decreased FA in the regions of superior corona radiata, the corpus 
collosum and the cingulum. This study reinforces importance of ProM in HIV. 
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INTRODUCTION 
 
Neuropsychological impairment is seen in up to 50% of  people infected with HIV-1, with 
the characteristic pattern of deficits reflecting a preferential disruption of prefronto-
striatal circuits (1).  Deficient episodic memory and retrieval are common in individuals 
with HIV-1 infection (2).  The memory profile of HIV-1-infection is most consistent with 
dysfunction in executive aspects of encoding and retrieval as seen in other “subcortical” 
disorders, such as Parkinson‟s and Huntington‟s diseases (2). 
 
Prospective memory (ProM), or “remembering to remember”, is an aspect of declarative 
memory that refers to the execution of a future intention (e.g., remembering to take 
one‟s medication).  Recent research shows that individuals infected with HIV report 
experiencing more frequent ProM failures as compared to demographically similar 
seronegative persons(3). A recent study showing that ProM demonstrates incremental 
ecological validity as a predictor of general IADL dependence in HIV (4). 
 
ProM generally involves a series of cognitive processes that includes: (a) the formation 
of an intention that is paired with a time or event; (b) maintenance of the intention-cue 
pairing over a delay interval while concurrently engaged in a other tasks, (c) detection 
and recognition of the cue; (d) search and retrieval from retrospective memory (RM) for 
the content of the intention; and (e) successful execution of the intention. (5) 
A distinction is often made between event-based (EB) and time-based (TB) ProM tasks 
(6) The difference between these two tasks concerns the type of cues that initiate 
retrieval of the intention. An external stimulus provides the cue for action in an EB task 
(e.g., grocery store cues the buying of bread), whereas in TB tasks, the intended action 
is performed after a specified time interval (e.g., taking a medication every six hours).  
 
Intact ProM is critical in order to properly adhere to a medication regimen; that is, one 
must first form the intention to take the medication at some point in the future then 
maintain the intention-cue pairing throughout the day despite the distraction of normal 
daily activities, detect and recognize the cue when it occurs (e.g., making dinner), recall 
the specific medication and directions, and finally, take the medication as instructed.  (7) 
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HIV-associated ProM impairment has emerged as a significant predictor of medication 
management, even after considering the contributions of executive functions, attention, 
episodic retrospective memory, and verbal fluency(8).  
 
Neuroimaging studies have been conducted to investigate ProM at a neural systems 
level.  During a ProM task, there was activation of the anterior prefrontal cortex (BA 10) 
on fMRI(9),  and the left frontal pole (BA 10), as well as right dorsolateral and 
ventrolateral prefrontal cortex (BA 8/9/47) and anterior cingulate (BA 24) in an earlier 
PET study. This is consistent with the hypothesis that anterior prefrontal cortex (area 
10) supports the biasing of attention between external events and internal cues.   
 
Given that white tracts from prefrontal cortex are involved in HIV(10), it might be 
hypothesized that in HIV damage to such tracts leads to ProM impairment.   Diffusion 
weighted imaging used to derive measures of fractional anisotropy (FA) in white matter 
tracts provides an indirect indication of the structural integrity of the regional white 
matter(11). Previous studies using DTI, arguably a more sensitive measure of white 
matter integrity than conventional structural MR sequences, have demonstrated frontal 
and internal capsular pallor in clinical studies of HIV-1 positive patients(10). As such, 
preliminary evidence suggests that there is white matter involvement in HIV associated 
neurocognitive disorder (HANDS), but as yet, no study of which we are aware has 
investigated the correlation with changes in white matter and ProM. 
We hypothesized that persons with HIV-1 infection would demonstrate impaired ProM 
relative to demographically comparable seronegative comparison subjects. We further 
hypothesized that ProM functioning in HIV would correlate with performance on 
neuropsychological tests of executive functioning, information processing speed, 
learning, and working memory, but not with measures of retention or semantic memory 
Finally, we hypothesized that HIV-1-infected individuals with poor ProM would 
demonstrate white matter changes reflected as lower FA using DTI in anterior prefrontal 
cortical white matter regions.  
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METHODS 
Subjects  
Participants (n=128) with HIV and healthy non-HIV controls (n=32), all aged 18-35 years 
were recruited from the Infectious Diseases Clinics within the Groote Schuur Hospital 
recruitment area. To be eligible HIV participants were required to have a positive 
diagnosis of HIV infection made within the last six months (based on serologic testing by 
ELISA and Western blot), to have not previously used anti-retroviral medications 
(“HAART naïve, and have at least 7 years of formal education.   
 
The presence of other current DSM-IV disorders determined through semi-structured 
interviews using the MINI was an exclusion criterion. Patients were also excluded if they 
were using psychotropic medication or had a recent (6 month) substance abuse history 
as defined by responses to the Alcohol Use Disorders Inventory (AUDIT) and the 
Substance Abuse and Mental Illness Screener (SAMISS) Individuals with a score 
greater than 16 on the Beck Depression Inventory (II) were excluded from the study.  
Patients were also excluded if they reported a lifetime history of head injury with loss of 
consciousness exceeding 30 minutes or a current neurological disease or infection. 
Controls, who attended the same ARV clinics as the subjects, had the same inclusion 
and exclusion criteria although they tested as being HIV negative.  
 
Procedure 
Participants completed clinical assessments in a single testing session. Neuroimaging 
was conducted within one week of the initial evaluation on 37 patients in the HIV 
positive cohort and on 10 controls. All measures were administered and scored 
according to standard procedures. Written informed consent was obtained prior to 
enrolment and exposure to any study related procedure. The protocol was approved in 
writing by the Committee for Human Research of the University of Cape Town.   
A neuropsychological test battery was administered to all participants to assess specific 
domains of attention, concentration, learning, memory psychomotor speed and 
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executive function. The battery was based on that used by the HIV Neurobehavioral 
Research Centre.  The neuropsychological test battery consisted of the following 
instruments:  Verbal Fluency tests (animal; fruit & vegetable); Digit Symbol and Symbol 
Search subtests from the Wechsler Adult Intelligence Scale – third edition (WAIS-III, 
Psychological Corporation, 1997); Trail making test Part A (TMT, Reitan 
Neuropsychology Laboratory, 1992); Hopkins Verbal Learning Test – revised (HVLT-R; 
Brandt & Benedict, 2001); Brief Visuospatial Memory Test – revised (BVMT-R, 
Benedict, 1997); Wisconsin Card Sorting Test (WCST 128-item version; Grant & Berg, 
2000); Stroop Colour and Word Test (Golden, 1978); Grooved Pegboard Test 
(Lafayette Instrument Company, 1989); Finger Tapping Test; Rey-Osterrieth Complex 
Figure (Rey, 1941 & Osterreith, 1944); Wechsler Memory Scale - Mental Control (WMS; 
The Psychological Corporation, Wechsler, 1997); Mental Alternation Test (Jones, Teng, 
Folstein & Harrison, 1993). Changes to word lists to reflect local language and idiom 
were made. All instruments had their instructions and content translated into isiXhosa 
and Afrikaans - instructions were also back-translated for fidelity.  The WCST 
perseverative error score was taken from the published norms generated through the 
report. The Stroop Interference scores were generated using Golden‟s (1978) 
methodology.  For the remainder of the test scores, raw scores were used given that 
published norms are not suitable for this population.  
A full neuromedical examination was conducted on all participants. Blood for CD4 cell 
counts was taken in the infectious diseases clinic.   
 
Prospective memory assessment 
ProM was assessed using a subjective self -report measure as well as objective 
measures.  Self-reported ProM was assessed using the ProM Scale from the 
Prospective and Retrospective Memory Questionnaire (PRMQ; Smith, Della, Sala, 
Logie, & Maylor, 2000), The objective measure consisted of both a time and an event 
based task.  The event based task was a measure previously used by Huppert et al., 
2000. The instructions were `Later on, I am going to give you a name and address to 
write on the envelope. When you have finished doing this, I would like you to do the 
following: turn it over, seal it and write your initials on the back. „Could you remember to 
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do this then without me reminding you?‟  This was followed by a delay interval of around 
10 minutes which was filled with other cognitive tasks. The interviewer then observed 
whether the respondent carried out the prospective memory task. If the respondent did 
not do so within about 10 seconds, the interviewer prompted `Were you going to do 
something else with the envelope' If only one correct action was carried out (i.e. just the 
envelope sealed or just initial written on the back), the interviewer said `Was there 
something else you were going to do‟.   The time based task was taken from the 
Memory for Intentions Screening Test (MIST) ( Raskin, 2004), which is a standardized 
laboratory measure of ProM with published evidence of its reliability  and construct 
validity (3). The instruction was:  'In 2 minutes ask me when this session ends today‟.  
Prospective memory scores were totaled across the tasks. The scores of the tasks 
completed without prompt were doubled in order to form a Total Prospective Memory 
Index. 
 
 
Brain Imaging 
Imaging was performed on a Siemens Magnetom 3T Allegra and occurred within 7 days 
of the screening and neuropsychological assessment. We acquired a multi-directional 
diffusion weighted sequence with 30 diffusion directions, 1 b=0 sec/mm2 direction, 
TR=8800 ms, TE=88 ms and a b-value=1000 sec/mm2. The images were acquired as a 
mosaic resulting in a 960 x 960 matrix with 60 slices per volume, and a corresponding 
in-plane spatial resolution and slice thickness of 2 x 2 mm2 and 2.2 mm, respectively. 
The 2.30 minute sequence was repeated three times and averages were derived.  
 
 
Image processing:  
Eddy current correction was performed separately in each of the three acquisitions 
using affine transformations in FSL (Oxford Center for MRI of the Brain, Oxford, UK).  
The data were then imported to MATLAB (The Mathworks Inc, Natick, MA) for further 
processing. Co registration was performed across the three acquisitions using affine 
transformations with the unweighted image of the first average as a reference. For each 
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of the three acquisitions, diffusion tensors were calculated and outliers were rejected by 
first calculating Z-scores based on 25 and 75 percentile limits, and then discarding data 
points more than 3 standard deviations away from the mean. The three acquisitions 
were then averaged and mean diffusivity (MD) maps were calculated. Diffusion tensors 
and fractional anisotropy (FA) images were then derived. An affine as well as a non-
linear registration of the B0 images to each subject‟s structural T1 image (intra-subject) 
was performed. The warps were applied to the FA images. A mean FA template was 
then created from all the subjects followed by a final registration and warp of all the FA 
images to the mean template. The same registration transforms were applied to the MD 
images. A general linear model ANOVA was performed on the FA and MD voxels of 
each cohort to determine significant differences between the groups. This was 
performed at a p<0.01 uncorrected threshold with a FA mask of 0.25.   
Comparisons between HIV-positive groups (good and poor ProM) and the healthy sero-
negative control (HC) group were then drawn to examine the associations between HIV 
infection, ProM and white matter FA. Whole brain voxel analysis of FA and MD in the 
control group was also compared to the HIV+ subgroups (good and poor ProM).   
 
Statistical Analysis 
Descriptive statistics, t-tests and Chi-square analyses, were performed to examine 
between-group differences on demographic variables. Because the assumptions of 
normality for ProM data were not met for this sample, non-parametric tests were 
performed. The Mann-Whitney test was used to assess between-group differences on 
measures of ProM. The self-report measure of the PRMQ was correlated with the 
objective measures of prospective memory.  In order to indicate which other cognitive 
domains bore the strongest relationship prospective memory in the current sample, 
Spearman‟s rho correlation coefficients were calculated to explore associations 
between the prospective memory total score and scores on the rest of the 
neuropsychological battery. Linear regression was performed in order to see which tests 
from the remainder of the battery were the best predictors of poor prospective memory.   
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RESULTS 
One hundred and sixty participants (HIV+ n=128 and seronegative controls n=32) were 
included in the final analysis. DTI was performed on a subsample of 40 HIV+ 
participants and 10 controls. The imaging data from 3 subjects in the HIV group were 
discarded due to movement artefacts. Age, education and gender in the HIV+ and 
control groups were tabulated (Table 1); the groups were not significantly different in 
terms of education or gender, but that the HIV group was significantly older.  
 
Table 1:  Demographic variables              Mean/SD  
Variable HIV+ 
(n=128) 
HIV- 
(n=32) 
Significance 
Age 29.62 (3.59) 24.53 (5.99) p = 0.000049 
Education 10.07 (1.94) 10.66 (1.45) p = 0.114 
Gender (M:F) 32:95 9:23 p = 0.833 
 
 
Total prospective memory was significantly poorer in HIV+ than in controls (p=0.023).  
Time-based ProM was decreased in the HIV compared to controls ((p=0.00004 without 
prompts, p=0.001) with prompts). Neither event-based ProM without nor with prompt 
differed between HIV+ and control groups.   
  
Good prospective memory was defined as those participants who were able to perform 
the ProM tasks without prompting. Using the good/poor prospective memory distinction, 
39.8% of HIV+ group had good prospective memory while 71.9% of the controls did. 
Similarly 60.2% of the HIV+ group had poor prospective memory while 28.1% of the 
controls did. 
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Table 2 
Good and Poor Prospective Memory 
    Prospective Memory 
Good Poor  Total 
 HIV+ Count 51 77 128 
% within HIVStatus 39.8% 60.2% 100.0% 
Controls Count 23 9 32 
% within HIVStatus 71.9% 28.1% 100.0% 
 
 
The associations between the Total Prospective Memory Summary score and the 
neuropsychological tests from the remainder of the battery are shown in Table 3.  There 
were a greater number of significant correlations with Total Prospective Memory score 
for the HIV+ group compared to controls.  Tests in motor function, leaning, working 
memory, processing speed, executive function and word fluency domains had 
significant correlations with Total Prospective Memory Summary score. Correlations 
that were not significant for both groups were those for Finger Tapping Test (dominant 
and non-dominant hands), HVLT Learning, Stroop Interference and WCST 
Perseverative Errors.  None of the tests of motor function in the control group correlated 
with the Total Prospective Memory Summary score. 
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Table 3:  Correlation between Total ProM summary score and neuropsychological 
tests 
Tests in their Domains HIV+ 
(n=128) 
Controls 
(n=32) Motor    
Finger Tapping Dominant -.140 -.314 
Finger Tapping Non-Dominant -.035 -.312 
Grooved Pegboard Dominant -.193* -.028 
Grooved Pegboard Non-Dominant -.253** .076 
Learning   
HVLT-R Total .376** -.075 
HVLT-R Learning -.015 .132 
HVLT-R Recall .419** .236 
HVLT-R Recognition .308** .170 
BVMT-R Total .405** .367* 
BVMT-R Learning .197* .210 
BVMT-R Recall .429** .280 
BVMT-R Recognition .279** .081 
Working Memory   
MAT .153 .407* 
WMS-III Mental Control .381** .384* 
Processing Speed   
WAIS- III Digit Symbol .434** .214 
WAIS- III Symbol Search .243** .342 
TMTA -.179* -.279 
Colour Trails I -.163 -.383* 
Executive Functions   
ROCF Copy .319** .273 
Colour Trails II -.218* -.303 
Stroop Word .329** .518** 
Stroop Colour .297** .618** 
Stroop Colour-Word .220* .474** 
Stroop Interference .007 .096 
WCST Perseverative Errors -.104 -.157 
Word Fluency   
Animal Fluency .543** .423* 
Fruit & Vegetable Fluency .378** .119 
*p=<0.05 
**p=<0.001 
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As poor retention and verbal fluency were associated with impaired ProM we assessed 
whether the results obtained here differ from those in previous research.  Previous 
studies have shown that retention  and recognition are less commonly affected in 
persons with HIV-1 disease(12).  T-tests found no significant differences between HIV+ 
and control participants in tests of word fluency (p=.717), verbal retention (p=.083)  and 
recognition(p=.077). This remained the case even when test language was controlled 
for and when only those tested in their first language were included. 
 
Stepwise linear regression models were used to examine the neuropsychological 
predictors of poor ProM. The overall model predicting poor ProM was significant F(3,95) 
= 18.387, p = 0. 00003, adjusted r2 = .347. Impaired performance on Semantic fluency 
(animals) (β = -.378, t = -4.332, p = . 00003), BVMT recall (β = -.274, t = -3.159, p = . 
002), BVMT recognition (β = .254, t = 3.139, p = . 002), HVLT recall (β = -.2, t = -2.359, 
p = . 02), and Colour trails I (β = .182, t = 2.310, p = . 023) were significant predictors of 
poor ProM. 
 
The Kruskal-Wallis test revealed that the time-based task without prompt was weaker in 
the HIV associated dementia (HAD) group than the asymptomatic group (p=.022) It 
suggests that the event-based task without prompt similarly distinguishes between 
dementia category groups (p=.028) as defined by the updated American Academy of 
Neurology criteria (13).. Both the time and event-based tasks with prompt did not 
distinguish between dementia category groups.  
Total Prospective Memory score correlated poorly with the self -report PRMQ 
(Spearman‟s rho R=.073) 
 
DTI 
Comparisons were performed to examine the effect of ProM on FA and MD. The 
seronegative control group was compared to HIV+ participants with good ProM and 
then again to those with poor ProM. The final comparison was between the 2 HIV 
positive groups (ie.  good vs poor ProM).  Those HIV+ participants with poor ProM had 
significantly decreased FA in the regions of superior corona radiata, the corpus 
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collosum and the cingulum when compared to those who were HIV+ with good ProM. 
We found increased FA in the Superior longitudinal fasciculus (left) in the HIV+ good 
ProM group compared to controls (p = 0.0024).  When comparing controls to HIV+ 
participants with poor ProM we found significant decreases in FA in the regions of the 
corpus collosum, the sagittal stratum and the superior longitudinal fasiculus.  Complete 
FA results are summarized in table 4.  No differences were found in MD in the 3 group 
comparisons. 
 
 
Table 4:  Significant FA decreases  
 
 
Poor ProM HIV+ vs HC 
(p < 0.01 uncorrected) 
 
Area P value 
 Genu of the CC (bilateral) p = 0.0029 
 Superior longitudinal 
fasciculus (right) 
p = 0.0062 
 Sagittal stratum (left) p = 0.00063 
Good ProM HIV+ vs 
poor ProM HIV+(p < 
0.01 uncorrected) 
Superior corona radiata 
right 
p = 0.0035 
 Genu of the corpus 
callosum bilateral 
p= 0.006 
 Cingulum near 
hippocampus (right) 
p = 0.0052 
 Cingulum near 
hippocampus (left) 
p = 0.0033 
 Posterior thalamic 
radiation (bilateral) 
p = 0.0067 
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Figures 1-2 show the output from the voxel-based analysis with the colour blobs 
indicating significant FA differences (p<0.01 uncorrected).  
 
 
Figure1:  Good ProM HIV+ vs. poor ProM HIV+ (p < 0.01 uncorrected):  Genu of the 
corpus callosum bilateral (p = 0.006) 
 
    
 
 
Figure2: Good ProM HIV+ vs. poor ProM HIV+ (p < 0.01 uncorrected):  Cingulum 
near hippocampus on left side (p = 0.0033) 
 
   
 
 
Linear regression models were created to determine the neuropsychological predictors 
of FA in the HIV+ cohort (n=37). Given the significant difference in age between the 
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controls and the HIV+ participants and the role that age pays in changes in the white 
matter, age was entered as a potential predictor in all of these models .However, it was 
not significant for any of the models..  Colour trails II (β = .305, t = 2.151, p = .044), 
HVLT learning (β = .425, t = 3.458, p = .002), and the Digit Symbol test (β = .415, t = 
3.254, p = .004) were significant predictors of FA scores in the superior corona radiata. 
Semantic fluency (animals) (β = .493, t = 2.717, p = .012) was a significant predictor of 
FA scores in the Genu of the CC and in the cingulum (β = .432, t = 2.295, p = .031)  
 
 
 
DISCUSSION 
Consistent with our original hypotheses, first, results from the current study provide 
evidence of ProM impairment in HIV+ patients. Furthermore ProM was worse for those 
with HAD. Second, ProM functioning in HIV+ patients correlated with performance on 
neuropsychological tests of executive functioning, information processing speed, 
learning, and working memory, but also with measures of retention or semantic 
memory. Third, HIV+ participants with poor scores of ProM correlated significantly with 
lower FA values when contrasted with subjects who were HIV positive, but did not have 
ProM impairment.  Although age was statistically different between the groups, it did not 
predict low FA in the HIV + cohort. 
The data here confirm previous work on ProM impairment in HIV. It is unlikely that 
findings from the current study are confounded by depressive symptoms or 
demographic factors such as level of education, as the HIV + and seronegative groups 
were comparable years of education, and sex. However, although in a previous study 
the HIV+ve sample demonstrated deficits in time-and event-based ProM,  we found that 
only time- based and total ProM, not event based ProM, discriminated between HIV+ 
and control participants. The sample size in our study is larger, or this may be due to 
differences in assessment of ProM.   It has been hypothesized that time-based tasks 
require slightly different cognitive processes than event-based tasks (i.e., a greater 
emphasis on self-initiated monitoring and retrieval), and empirical evidence suggests 
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that the former are generally more sensitive in older adults (14) and traumatic brain 
injury samples (15). 
Specific correlations were observed between the Total Prospective Memory score and 
tests of executive functioning, information processing speed and verbal working 
memory within the HIV+ve sample. This is not surprising given either previous literature, 
or the relationship ProM has to these cognitive domains.  People infected with HIV often 
exhibit dysfunction in the executive aspects memory tasks(3) Difficulties in executive 
function include a disorganized plan for retrieving the correct information from episodic 
memory stores and would manifest in poor ProM performance(3) Nevertheless, a 
previous study of ProM in HIV ,with a smaller sample size, found that ProM 
performance did not correlate with measures of semantic memory, retention, or 
recognition discrimination .  However consistent with previous literature verbal fluency 
and HVLT recognition and recall did not discriminate well between HIV+participants and 
controls(16). 
Previous findings on the relationship between subjective and objective measures of 
cognitive performance suggest a relatively weak association in healthy volunteers(17).  
In our study PRMQ scores correlated poorly with Total Prospective Memory score.  The 
underlying relationship between awareness of prospective memory impairment in HIV 
infection is unknown.   
Results of the present study using DTI to contrast HIV + participants with poor ProM to 
HIV+ participants with good ProM, confirm our hypothesis in which we anticipated 
changes associated with poor ProM in white matter tracts that relay through the anterior 
prefrontal cortical regions including the corpus callosum, the cingulum (hippocampus) 
and the superior corona radiata.  These findings provide evidence that the poor ProM is 
associated with neural changes induced by HIV. ProM requires retrospective memory 
(and thereby medial temporal and limbic structures such as the hippocampus).  This is 
consistent with the neuropsychological findings that failures in retrospective recall (i.e., 
forgetting the content of an intention) will result in ProM failure (18).  Colour trails 1&2, 
HVLT learning, the Digit Symbol test and semantic fluency predicted reduced FA in the 
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superior corona radiata and semantic fluency in the corpus callosum and cingulum, 
suggesting that these neuropsychological tests may be sensitive to white matter 
damage in clade C HIV.  It is possible that this may be a clade-specific difference, 
wherein we found that HIV+ participants performed as well as sero negative controls on 
the Grooved Pegboard Test, a measure consistently used to ascertain whether HIV- 
associated subcortical neuropathology exists (19;20). Previous DTI studies in clade B 
found correlations between motor speed losses and poor white matter integrity of the 
corpus callosum(21) 
Limitations of our study are that our HIV negative control group is small  Our scanned 
sample size is also small and our data are cross- sectional and as such are not able to 
address the question of whether white matter changes noted in participants with poor 
ProM represent an early marker of subsequent cognitive decline.  A more 
comprehensive objective assessment of ProM such as the MIST may be useful in future 
work.  
Despite these limitations this is the first study of which we are aware which has shown 
changes in white matter associated with ProM in HIV + participants. The prevalence of 
ProM impairment in our HIV+ve sample potentially carries profound clinical implications 
in terms of their possible impact on independent living skills(8) and the risk of 
nonadherence to complex antiretroviral medication regimens(7).  Such findings imply 
that assessment and consideration of the ProM deficits associated with HIV infection 
might be useful in the day-to-day management of the disease.  For example medication 
adherence efforts might also be enhanced by keeping to a minimum the number and 
complexity of tasks to be completed.  Future research could focus on intervention 
strategies for persons infected with HIV who have poor ProM, and on longitudinal study 
designs that may identify ProM as a reliable early correlate of risk for subsequent 
cognitive dysfunction in HIV 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM: INTERVIEW AND NEUROPSYCHOLOGICAL 
ASSESSMENT: CONTROLS 
 
TITLE OF THE RESEARCH PROJECT: Neurocognitive disorders in young 
adults with HIV/AIDS commencing anti-retro-viral treatment in the Western 
Cape  
 
PRINCIPAL INVESTIGATOR: Dr John A. Joska 
 
ADDRESS: Department of Psychiatry and Mental Health, J-block, Groote Schuur 
Hospital, Anzio Road, Observatory, 7925 
 
CONTACT NUMBER: 021- 404 2164/021- 4042151 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town and will be conducted according to 
the ethical guidelines and principles of the international Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this research study all about? 
 The study will be conducted at the primary care antiretroviral clinics in 
Khayalitsha site C, Woodstock and Mitchells Plain. The study aims to include 
200 HIV positive people and 50 HIV negative people. 
 This study will perform a detailed interview and neuropsychological assessment 
when people start taking anti-retrovirals and again at one year, to find out if there 
are any problems in thinking or moving in people with HIV/AIDS. This is in order 
to understand why certain people with HIV/AIDS develop these problems.  We 
will also do these assessments on the 50 HIV negative people.      
  You will also be asked for a sample of blood. This will be used to look at your 
body’s response to infection with HIV. Tests of inflammation will be done. This 
will help us to understand if inflammation is important in the way that problems in 
thinking and memory happen in people with HIV/AIDS. The study will require 
about 30 mls (two tablespoons) for this purpose. This will involve minor 
discomfort at the time taking blood and may cause some reddening and bruising 
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of your arm in this area. You may choose not to participate in this part of the 
study. 
 Some people will be asked to have a type of brain scan which will be done at the 
Cape Universities Brain Imaging Centre at Tygerberg Hospital. This scan is 
called an MRI (magnetic resonance imaging) scan. The scan will require you to 
lie on your back on a table that will move into the scanning machine for the 85 
minutes it will take for the scan. During this time you will be able to close your 
eyes and rest. You will also be able to talk to the study doctor/assistant at all 
times during the scan if you should experience any discomfort. The scan is a 
safe procedure if you have been screened correctly for the presence of any 
magnetic material on or inside you such as pace-makers, surgical clips and 
metal objects in the eyes. A formal screen for this will be done at the screening 
visit by a member of the study team. As the scan is done in a relatively confined 
space, occasionally people become anxious. This does not happen often, and if 
you feel anxious, we will spend time allowing you to get used to the surroundings 
before we begin. When the magnet in the machine is switched on, it will make 
some loud banging noises, but you will be clearly warned when this will take 
place. At this time you will feel nothing and the noise is not harmful to you in any 
way. To minimise the possible discomfort associated with this, we will give you 
some soft earplugs and will also put earphones on so that you can listen to 
music if you so choose 
 Apart from these tests, the study will not offer special treatment or medication. If 
a mental health problem is found, you will be referred for treatment at your 
nearest clinic.  
 
Why have you been invited to participate? 
 You have been invited to participate, because memory and thinking problems in 
HIV/AIDS are not properly understood by medical science. We also need to 
compare these problems in people with and without HIV to see if there are 
differences. 
 
What will your responsibilities be? 
 You will be required to attend the study visit on time and to participate as fully as 
possible. This means that you will answer questions as fully and honestly as 
possible. If there are questions you do not want to or cannot answer, you should 
say so.   
 
Will you benefit from taking part in this research?  
 You will receive little benefit directly from the study.  If you do have a mental 
health problem, we will be able to refer you to someone who may help. Second, 
if any memory or thinking problems are identified, we will be able to explain 
these to you. In addition, information from this study may allow us to understand 
these problems better, and to develop studies which will help us to treat them 
better.   
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Are there in risks involved in your taking part in this research?  
 This study may make you feel uncomfortable as you talk about mental health 
problems. You may feel embarrassed or shy. Also, some people feel that is it 
better not to know about memory or thinking problems. 
 These are the main risks. You should feel free to mention your feelings or 
concerns to any member of the study team 
 
If you do not agree to take part, what alternatives do you have? 
 You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
 The information collected about you will be treated as confidential and protected.  
If it is used in a publication or thesis, your identity will remain anonymous.  Only 
the direct study team will have full access to the information. If we need to refer 
you to a clinic for treatment, we will provide them with the relevant information 
needed to treat your condition.  
 
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part in the study but your transport costs will be covered for 
the study visit- The study nurse will give you R150 for this. She will also provide the 
money it costs to attend the clinic. There will be no costs involved for you, if you do take 
part. 
 
Is there any thing else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part 
in a research study.   
 You can contact Dr John Joska at tel 021-4042164 if you have any further 
queries or encounter any problems. 
 You can contact the Research Ethics Committee of the Health Sciences Faculty 
of the University of Cape Town 021-4066338 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
 If you would like a copy of this information and consent form for your own 
records, please ask a member of the study team to give you one. 
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Declaration by participant/guardian/treatment partner (circle) 
 
By signing below, I ………………………………….. agree/agree on behalf 
of………………………… to take part in a research study entitled: “Neurocognitive 
disorders in young adults with HIV/AIDS commencing anti-retro-viral treatment in the 
Western Cape”. 
 
I declare that (delete whichever is NOT applicable): 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that my taking part/my relative or friend’s participation in this 
study is voluntary and I/we have not been pressurised to take part. 
 I/my relative or friend may choose to leave the study at any time and will not 
be penalised or prejudiced in any way. 
 I/my relative or friend may be asked to leave the study before it has finished, 
if the study doctor or researcher feels it is in my best interests, or if I do not 
follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 200_. 
 
 
 
 ..............................................................   ............................................................ 
Signature of participant/guardian/treatment partner Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2005. 
 
 
 ..............................................................   ............................................................ 
Signature of investigator Signature of witness 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM: INTERVIEW AND MRI 
 
TITLE OF THE RESEARCH PROJECT: Neurocognitive disorders in young 
adults with HIV/AIDS commencing anti-retro-viral treatment in the Western 
Cape  
 
PRINCIPAL INVESTIGATOR: Dr John A. Joska 
 
ADDRESS: Department of Psychiatry and Mental Health, J-block, Groote Schuur 
Hospital, Anzio Road, Observatory, 7925 
 
CONTACT NUMBER: 021-404 2164/021-4042151 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Research Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town and will be conducted according to 
the ethical guidelines and principles of the international Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this research study all about? 
 The study will be conducted at the primary care antiretroviral clinics in 
Khayalitsha site C, Woodstock and Mitchells Plain. The study aims to include 
200 HIV positive people and 50 HIV negative people. 
 This study will perform a detailed interview when people start taking anti-
retrovirals and again at one year, to find out if there are any problems in thinking 
or moving in people with HIV/AIDS. This is in order to understand why certain 
people with HIV/AIDS develop these problems. You will also be asked to provide 
a sample of blood- you will sign a separate form to provide this blood sample. 
You can decide not to give this sample if you wish, without it affecting any 
treatment you may receive. This blood sample will help us to understand HIV 
better in the future. Some people will be asked to undergo a brain scan. 
 Patients who are eligible to enter to the study will be asked to sign this form. 
They will then have 2 interviews on one day of about 2 hours each, where they 
will be asked questions about themselves and their mental health. You will be 
given a break during these interviews and given refreshments. You will perform 
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certain tests, like memory tests and movement tests. The interviews (without 
blood tests) will be repeated at one year. 
 Not everyone who comes to the clinic will be asked to participate. We will choose 
people who are eligible, depending on if they have other mental problems or not..  
 Apart from the interviews and tests, the study will not offer special treatment or 
medication. If a mental health problem is found, you will be referred for treatment 
at your nearest clinic. Any treatment related to HIV/AIDS you will also receive at 
your normal clinic. 
 
Why have you been invited to participate? 
 You have been invited to participate, because memory and thinking problems in 
HIV/AIDS are not properly understood by medical science. Younger people with 
these problems may demonstrate more clearly why they develop, in order for us 
to detect and treat these problems better in the future.  
 
What will your responsibilities be? 
 You will be required to attend the study visits on time and to participate as fully 
as possible. This means that you will answer questions as fully and honestly as 
possible. If there are questions you do not want to or cannot answer, you should 
say so.   
 
Will you benefit from taking part in this research? 
 You will benefit directly from the study in 2 main ways- first, a detailed mental 
health interview will be conducted, which will allow us to diagnose and treat any 
problems you may have. Second, any memory or thinking problems will be 
diagnosed, which will allow us to treat them if possible, but also to provide you 
with the assistance you need to manage with HIV/AIDS. In addition, information 
from this study may allow us to develop possible treatments for these problems, 
and to develop studies which will help us to understand these problems better.   
 
Are there in risks involved in your taking part in this research? 
 This study may make you feel uncomfortable as you talk about mental health 
problems. You may feel embarrassed or shy. Sometimes painful information is 
shared. Also, some people feel that is it better not to know about memory or 
thinking problems. 
  During the second visit in this study you will have a type of brain scan which will 
be done at the Cape Universities Brain Imaging Centre at Tygerberg Hospital. 
This scan is called an MRI (magnetic resonance imaging) scan. The scan will 
require you to lie on your back on a table that will move into the scanning 
machine for the 85 minutes it will take for the scan. During this time you will be 
able to close your eyes and rest. You will also be able to talk to the study 
doctor/assistant at all times during the scan if you should experience any 
discomfort. The scan is a safe procedure if you have been screened correctly for 
the presence of any magnetic material on or inside you such as pace-makers, 
surgical clips and metal objects in the eyes. A formal screen for this will be done 
Un
ive
rsi
ty
Of
 C
ap
e T
ow
n 
 
 
Informed Consent, Version 1, dated 06 Feb 2009 
                                           Initials________________ 
  
 
 Page 3 of 4 
at the screening visit by a member of the study team. As the scan is done in a 
relatively confined space, occasionally people become anxious. This does not 
happen often, and if you feel anxious, we will spend time allowing you to get 
used to the surroundings before we begin. When the magnet in the machine is 
switched on, it will make some loud banging noises, but you will be clearly 
warned when this will take place. At this time you will feel nothing and the noise 
is not harmful to you in any way. To minimise the possible discomfort associated 
with this, we will give you some soft earplugs and will also put earphones on so 
that you can listen to music if you so choose.  
 These are the main risks. You should feel free to mention your feelings or 
concerns to any member of the study team 
 
If you do not agree to take part, what alternatives do you have? 
 You are free not to participate or to withdraw at any time during the study. Your 
treatment will not be affected in any way. You may continue to attend your clinic. 
It would be helpful for the study team to let us know why you have decided not to 
take part, but you are free to not give a reason. 
 
Who will have access to your medical records? 
 The information collected about you will be treated as confidential and protected.  
If it is used in a publication or thesis, your identity will remain anonymous.  Only 
the direct study team will have full access to the information. If we need to refer 
you to a clinic for treatment, we will provide them with the relevant information 
needed to treat your condition.  
 
Will you be paid to take part in this study and are there any costs involved? 
 
You will not be paid to take part in the study but your transport costs will be covered for 
each study visit- The study nurse will give you R150 for this. She will also provide the 
money it costs to attend the clinic. There will be no costs involved for you, if you do take 
part. 
 
Is there any thing else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part 
in a research study.   
 You can contact Dr John Joska at tel 021-4042164 if you have any further 
queries or encounter any problems. 
 You can contact the Research Ethics Committee of the Health Sciences Faculty 
of the University of Cape Town 021-4066338 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
 If you would like a copy of this information and consent form for your own 
records, please ask a member of the study team to give you one. 
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Declaration by participant/guardian/treatment partner (circle) 
 
By signing below, I ………………………………….. agree/agree on behalf 
of………………………… to take part in a research study entitled: “Neurocognitive 
disorders in young adults with HIV/AIDS commencing anti-retro-viral treatment in the 
Western Cape”. 
 
I declare that (delete whichever is NOT applicable): 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that my taking part/my relative or friend’s participation in this 
study is voluntary and I/we have not been pressurised to take part. 
 I/my relative or friend may choose to leave the study at any time and will not 
be penalised or prejudiced in any way. 
 I/my relative or friend may be asked to leave the study before it has finished, 
if the study doctor or researcher feels it is in my best interests, or if I do not 
follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 200_. 
 
 
 ..............................................................   ............................................................ 
Signature of participant/guardian/treatment partner Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 200_. 
 
 
 ..............................................................   ............................................................ 
Signature of investigator Signature of witness 
U
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
Sticker:
CD4 J Scoresheet
HIV-associated neurocognitive disorders study: Neuropsychological Test Summary Sheet
Name Gender: M          F
Date of examination (DD.MM.YYYY) Years of education:
Date of birth (DD.MM.YYYY) Age:
Examiner:      JL      JX      JJ Handedness: R                     L
Examined in: English Xhosa Afrikaans
A: Motor function Z = (x-X)/SD
A1: Successive Finger Taps Raw Score Mean SD Deviation from mean
D(sec): (              ) (              )
ND(sec): (              ) (              )
A2: Grooved pegboard
D(sec): (              ) (              )
ND(sec): (              ) (              )
B: Learning and memory
B1: Hopkins Verbal Learning Test
Raw Score Mean SD Deviation from mean
Trial 1
Trial 2
Trial 3
Total
Learning
DR                     (               %)
Recognition: true positives Discrimination index (True positives - false positives)
false positive errors:    related (          )  unrelated (          )  
B2: Rey Complex Figure raw score mean SD Deviation from mean
Copy
3 min recall
delayed recall
B3: Brief Visuospatial Memory Test
Form   1    2    3    4    5    6 Raw Score T-score Percentile Deviation from mean
Trial 1
Trial 2
Trial 3
Total recall
Learning
Delayed recall
Percent retained
Recognition hits
Recognition false alarms
Recognition Discriminatin Index
Recognition response bias
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B: Learning and memory
B4: Prospective Memory Test
C: Attention
C1: Mental alternation test
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Raw Score Mean SD
ii.alphabet raw score                       s errors score Deviation from mean
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z mean                              s      sd              s
1  2  3  4   5   6   7   8   9  10 11  12   13   14   15   16   17     18   19   20  21   22   23   24   25   26
A  B C D  E   F  G   H    I    J K    L   M     N     O    P    Q      R     S     T    U     V      W      X      Y     Z
C2: WMS III Mental Control raw score                       SS Deviation from mean
C3: WMS III- spatial span Raw Scores (SS) Deviation from mean
Forward:                (             ) Backward             (             ) Total                    (                    )
D: Speed of processing Raw Score (Scaled Score)
D1: WAIS III: Digit symbol coding (               )
D2: WAIS III: Symbol search (               )
E: Executive function
E1: Trail-making  RS Percentile T-score SD Deviation from mean
Test A
E2: Color Trail-Making
i.part 1
ii.part 2
E3:Stroop Colour and Word Testxpected residual T (table IV)
Word
Colour
colour word
Interference
E4: Wisconsin Card Sorting Test
Categories completed
Trials to first category
Failure to maintain set
Learning to learn
F: Language
G1: Category fluency test Raw Score Mean SD Deviation from mean
i.animals
ii. Fruit and vegetables
G: Intelligence
WASI Raw score SS Deviation from mean
Vocabulary test
Block design
Similarities
Matrix reasoning
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
